According to the research summary, the objective of the study was to evaluate the perioperative and long-term outcomes associated with extrapleural pneumonectomy for patients with malignant pleural mesothelioma. Pleural mesothelioma affects the lining of the chest cavity and lungs. Other forms of mesothelioma include pericardial, which affects the lining of the heart and is extremely rare; and peritoneal, which affects the lining of the abdomen. Mesothelioma is atributed almost exclusively to asbestos exposure.

According to the Multimedia Manual of Cardiothoracic Surgery, extrapleural pneumonectomy was introduced in the 1940s for the treatment of extensive infections of the lung and pleural space. Over the past 20 years, the extrapleural pneumonectomy technique has been modified and applied to the treatment of locally advanced malignant pleural mesothelioma, achieving substantial reductions in mortality. The surgery involves the removal of the lung with visceral and parietal pleurae, pericardium and diaphragm.

Researchers selected 70 patients between October 1994 and April 2008 to undergo the procedure. Prognostic factors included age, gender, side of disease, asbestos exposure, histology, positron emission tomography, date of surgery, neoadjuvant chemotherapy, completeness of cytoreduction, lymph node involvement, peioperative morbidity, adjuvant radiotherapy and pemetrexed-based chemotherapy.

The mean age of patients was 55 years. The median survival was 20 months, with a 3-year survival of 30 percent. Analyses showed improved survival for patients with asbestos exposure, negative lymph node involvement, and receipt of adjuvant radiation or postoperative pemetrexed-based chemotherapy.

The study was conducted by physicians from the University of Sydney, Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital; The Baird Institute for Applied Heart and Lung Surgical; Department of Medical Oncology, Sydney Cancer Center, Royal Prince Alfred Hospital; and Department of Radiation Oncology, Sydney Cancer Center, Royal Prince Alfred Hospital; all in Sydney, Australia.

SOURCE: myMeso › Study supports extrapleural pneumonectomy to treat select mesothelioma patients

Warnex is a life sciences company providing laboratory services to the pharmaceutical and health care industries. The company will market the miRview™ products and will send samples gathered from the tests from Canada to the Rosetta Genomics laboratory in Philadelphia for analysis. Warnex has three facilities, located in Laval and Blainville, Quebec, and Thunder Bay, Ontario.

We’ve written about the miRview™ products on this site in the past. They include miRview™ mets, which can identify the primary tumor site in patients presenting with metastatic cancer; miRview™ squamous, which differentiates squamous from non-squamous, non-small cell lung cancer (NSCLC); and miRview™ meso, which leverages microRNA’s high specificity as biomarkers to differentiate mesothelioma from other carcinomas in the lungs.

All three of the miRview tests utilize MicroRNA technology. According to Rosetta Genomics, microRNAs (or miRNAs) are recently discovered, naturally occurring, small RNAs that act as master regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. This is because microRNAs have been shown to have different expression in various pathological conditions, the observation of which can provide a novel diagnostic tool for many diseases.

According to Rosetta Genomics, the miRview™ meso product is a highly accurate test that can help physicians to more easily identify mesothelioma, which can be hard to differentiate from other cancers. The test also can help rule out a meso diagnosis in patients who have been diagnosed with adenocarcinoma of the lung and who also have been exposed to asbestos, which is known to cause mesothelioma.

SOURCE: myMeso › Warnex will distribute mesothelioma biomarker test in Canada

The study was headed by Shinji Sasada of the Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan. Scientists compared specimens obtained using the IT knife, as compared to standard flexible forceps (SFF) during semirigid pleuroscopy, and resulting diagnoses, in 20 patients. Subjects all had unexplained pleural effusion.

Results revealed that the IT knife biopsy was superior to SFF in 8 of 20 patients, produced diagnositc yields from specimens in 85 percent of cases (17 of 20 cases) versus 60 percent of cases using SFF (12 of 20 cases).

Researchers conluded that “electrocautery biopsy using the IT knife during semirigid pleuroscopy has great potential for diagnosing smooth abnormal pleura which are difficult to biopsy with SFF.”

SOURCE: myMeso › New technology improves mesothelioma diagnosis from biopsy

This week, university researchers announced they are ready to begin recruiting current and former taconite workers on Minnesota’s Iron Range, and their spouses, to participate in a screening program.

Preliminary research actually began in Summer 2007, but got a boost from the legislature’s funding, allowing the study to expand significantly. The funding established the Minnesota Taconite Workers Lung Health Partnership task force.

There are four health studies associated with the project:

• a motality study under the direction of the Minnesota Department of Health related to miner deaths
• a cancer rate incidence study
• a respiratory health assessment for miners or former miners
• an occupational exposure study

According to an update in the Star Tribune, which serves the Twin Cities, Minneapolis and St. Paul, “since last year, researchers have been collecting data they need to determine why Iron Range miners die from mesothelioma at higher rates than others.”

Researchers hope to recruit around 1,200 current and retired workers for the new screenings, plus about 800 of their spouses.

Mesothelioma has been linked exclusively to asbestos exposure, so this study seeks to determine what similarities may exist in the taconite mining industry and the taconite mineral that produce high incidences of mesothelioma among its workers.

SOURCE: myMeso › Minnesota mesothelioma study to begin testing taconite miners

Asbestos industry documents from as early as 1924 indicate that manufacturers knew there was a danger to workers who inhaled asbestos fibers.

Then in 1953, Dr. Irving Selikoff, a pulmonary specialist, began studying the link between asbestos exposure and lung disease. He noted a much higher percentage of lung disease among workers who inhaled asbestos fibers. Selikoff’s groundbreaking findings about of the occupational danger of asbestos expsoure was published in 1964.

And yet, it wasn’t unitl the mid-1970s that asbestos use was widely banned, and even today, its use is not completely banned.

Selikoff hoped his findings would make the future brighter for workers, protecting them from such devastating illnesses as those suffered by the generations who had come before.  Sadly, Selikoff passed away in 1992, before ever seeing asbestos eliminated in America, or seeing the threat of mesothelioma become a thing of the past.

With such clear evidence of the link between asbestos and mesothelioma, why is this still even a question??

SOURCE: myMeso › Selikoff study proved link between asbestos, mesothelioma in 1964

Peritoneal mesothelioma affects the lining of the abdomen, and makes up about 10-15 percent of all mesothelioma diagnoses. The more common form of mesothelioma is pleural, which affects the lining of the chest and lungs. All mesothelioma is linked to asbestos exposure.

The current “best practice” for the treatment of mesothelioma is a multi-modality approach, which is a combination of surgery and chemotherapy, along with immunotherapy.

“It’s a sequence of treatments that make sense,” Dr. Chabot explained.

However, Dr. Sugarbaker pointed out, only a small fraction of mesothelioma patients receive multimodality treatment.

“So many more things could be done to manage the treatment of this rare disorder,” Dr. Sugarbaker said. “We should have accumulated many thousands of data points on people with peritoneal mesothelioma. Unfortunately, a majority of patients in the U.S. do not get to a treatment center.”

There are still only a handful of treatment centers that specialize in mesothelioma, and even then there are distinctions in the treatment of peritoneal or pleural mesothelioma that narrows the field even further. Also, there are not a large number of physicians currently treating mesothelioma, and no established surgical training programs specifically for this field to develop more doctors experienced in mesothelioma treatment.

Awareness also is still an issue. Many patients are diagnosed too late for effective treatment.

Even if awareness is high and a patient is diagnosed early enough to be a viable candidate for successful mesothelioma treatment, the logistics of receiving treatment can be difficult. Most of the centers for mesothelioma treatment are located on the East Coast. There is one on the West Coast, but almost no options in the Midwest or other areas of the country. Treatment is usually extended over many months, making it necessary for patients to relocate to be near a treatment center if they are not lucky enough to live nearby.

“People often move and rent temporary housing. People live in trailers,” Dr. Chabot said. “More advocacy is needed to provide patient and family support for treatment. The travel issues for people who need treatment are huge.”

The Mesothelioma Applied Research Foundation, which sponsors the annual Meso Symposium, is laying the groundwork to facilitate discussions and establish a collaborative strategy, simply by bringing together the experts in this field. There is an emphasis now on forming a consortium to establish a new standard of care, and to try to combine the knowledge of the existing research and treatment centers, and to expand access to that research and treatment.

But, the experts acknowledge, there is still much to do.

SOURCE: myMeso › Access to mesothelioma treatment limited, difficult

This annual symposium is “for everybody” affected by mesothelioma. This includes patients, caregivers and family members, and those who have lost a loved one to mesothelioma, as well as advocates and scientific and medical experts. The event is designed to provide education about new research and treatment, to assist meso patients and their families and loved ones with coping skills and a network of support, and provide advocates with the tools to help make an impact in the effort to raise awareness about mesothelioma and the dangers of asbestos exposure, and to raise funds for research.

“I don’t think any community knows more about holding onto hope in the midst of difficult circumstances than mesothelioma patients and their families, ” said MARF executive director Chris Hahn. “But there is still a perception of mesothelioma as an orphan disease. It is overlooked, by the government, by the average person, despite the huge presence of asbestos in our society,” he said.

Mesothelioma is a deadly cancer that affects the lining of the chest wall or, more rarely, the abdomen, and, in very rare instances, the heart. It is caused by exposure to asbestos, and may have a latency period of up to 40 years or more from the time of exposure until symptoms manifest. It is difficult to diagnose, and often is misdiagnosed until too late for effective treatment. Even if diagnosed early, treatment is often difficult, and there is currently no known cure.

The Mesothelioma Applied Reserach Foundation is the largest independent program for mesothelioma reserach and support in the world. It operates a competitive grant program that awards up to 10 grants, or $10 million, each year to research projects most likely to lead to better treatment.

The Foundation is a non-profit organization whose main mission is dedicated to “eradicating the life-ending and vicious effects of mesothelioma.”

MARF needs funding. This is the only organization dedicated to the research and treatment of mesothelioma, but it is facing the same struggles that many other charitable foundations are facing in this tough economy – donations are down, funding is stretched thin. The foundation received 59 grant applications in 2008 – programs that WANT to explore and investigate mesothelioma in search of earlier diagnosis, better treatment methods and, ultimately a cure. But the Foundation was only able to fund five new programs in 2008.

It is estimated that 3,300 new cases of mesothelioma will be diagnosed each year.

Mesothelioma, once considered an industrial disease affecting primarily older men, is being diagnosed in younger and younger people. In 2008, a 3-year-old girl was diagnosed with mesothelioma. Mesothelioma is everybody’s problem. We cannot afford NOT to support mesothelioma research.

For more information about the Mesothelioma Applied Research Foundation and how to make a donation, visit them online.

The Foundation also needs volunteers. There are a number of ways you can help, from advocacy efforts to planning a fund-raising event, to simply helping put out the word about mesothelioma and the effects of asbestos exposure. You can find that information on their web site, too.

This was my first experience at the Symposium, and it was emotionally and intellectually exhausting, and inspiring, and motivating. I met some amazing people who, despite being personally devestated by mesothelioma, are determined to keep fighting. I’m amazed by this great group of folks.

I plan to add many more stories from information presented at the conference, and from the people I met there, in the next several days, so please check back! It’s too much to tell in one post!

SOURCE: myMeso › Mesothelioma community rallies to raise awareness, find a cure

During the Tribute Ceremony, MARF will create a collage of photos of these loved ones who have passed away. I would be more than honored to carry your photo to Washington to add to this Tribute. You may send your photo electronically, by email, and I will make color prints to add to the collage. Please let me know if you would be interested in this. You can email mymeso@gmail.com or email me directly at wendi.lewis@beasleyallen.com.

On Thursday, I also will have the opportunity to visit Capitol Hill to ask our congressional representatives to provide federal funding for mesothelioma research and treatment, and for the ban of asbestos. Please take a moment to sign the petition for these endeavors – there is a link on our home page.

I look forward to attending the Symposium next week, and will be blogging from the conference, which will provide a wealth of information about the latest progress in mesothelioma research and treatment. The conference begins on Thursday, June 25, with the visits to Capitol Hill, and continues through Saturday featuring distinguished physicians, researchers and advocates. I’m sure there will be a lot of valuable information to share.

God bless you all!

SOURCE: myMeso › May I remember your loved one at the Meso Symposium Tribute Ceremony?

Debbie was diagnosed with mesothelioma in November 2006, at which time her doctor gave her only a few months to live. That was when Debbie began looking for new treatments. She began chemoembolization in May 2008.

Chemoembolization, which is being pioneered by Dr. Thomas J. Vogl at J.W. Goethe University Hospital at Frankfurt University, introduces chemotherapy directly into a tumor, where it is basically sealed off so that it is concentrated in the area of need. The clinical trial started three years ago, and will continue for about two more years. The treatment is only available at the clinic in Germany.

Recently, BBC News featured Debbie and her efforts to bring chemoembolization to the UK, and beyond.

Watch the video.

SOURCE: myMeso › Debbie hopes to make groundbreaking mesothelioma treatment more widely available

If you live in the Ormond Beach area, it’s not too late to participate! The event is set for 1-3 p.m., with registration beginning at the bowling alley at noon. The $15 registration fee includes three games, lunch and a t-shirt. Proceeds will benefit the Mesothelioma Applied Research Foundation, which is the national organization dedicated to eradicating mesothelioma as a life-ending disease.

If you are not able to participate in the event, you can still make a donation. Mail your contribution to Tara’s attention at 11 Woodgate Court, Ormond Beach, FL, 32174. For more informatin, you can email Tara at tmusic1@cfl.rr.com or call 386-405-8264.

SOURCE: myMeso › Reminder: Bowlathon meso fundraiser tomorrow

The event is being organized by Tara Music, in honor of her father, Ray Beltrami. He was diagnosed with meso in January 2008, and passed away July 1, 2008.

“Because I could not do anything to save him, I have felt the need to spread awareness about this horrific disease,” Tara says.

For more information, contact Tara at tmusic1@cfl.rr.com or call 386-405-8264. If you are on Facebook, you can visit the MyMeso page to find a link to this event. A map to this event is available.

If you are not able to attend, but would like to make a donation, you can mail your contribution to Tara’s attention at 11 Woodgate Court, Ormond Beach, FL, 32174.

SOURCE: myMeso › Bowlathon to benefit mesothelioma research

The conference will feature prominent physicians, scientists, safety and health directors, as well as survivors, who will present current information about the status of asbestos in the U.S. and worldwide. Discussion will include facts on exposure, asbestos-related diseases and how to prevent them, and where to turn for help.

In addition to the main event on Saturday, there will be an evening reception on Friday, March 27, featuring musician Jordan Zevon, whose father, legendary singer-songwriter Warren Zevon, died of mesothelioma in 2003; and a Unity and Hope Remembrance Brunch on Sunday, March 29.

Five individuals will be honored for their outstanding work in raising awareness about asbestos exposure: U.S. Senator Barbara Boxer for her work to ban asbestos in the U.S.;  Margaret Seminario, AFL/CIO, for her efforts to unite, educate and empower asbestos victims and workers; Dr. Stephen Levin, MD, for his research into the social and medical impact of asbestos; and Pralhad Malvadkar and Raghunath Manwar for their work with victims of asbestos exposure in India and worldwide.

The conference is presented by ADAO, the Barbara Ann Karmanos Cancer Institute and the International Ban Asbestos Secretariat.

For more information or registration, visit ADAO online.

SOURCE: myMeso › Asbestos Awareness Conference set for March 28

The company reports a drop in cash and cash equivalents to $2 million, down from $4.7 million in July 2008. However, the company received $1.1 million from the sale of state tax loss carryforwards in New Jersey in December 2008, and says its cash reserves “are sufficient to support its activites into the fourth quarter of fiscal year 2009,” according to the report.

Following the Phase IIIb clinical trial, it was determined ONCONASE results in a statistically significant improvement in survival for patients with unresectable malignant mesothelioma who have failed one prior chemotherapy regimen. This represents a currently unmet medical need, and Alfacell will meet with the Food and Drug Administration in January 2009 to discuss details of its planned New Drug Application submission.

According to information provided by Alfacell, “ONCONASE is a first-in-class therapeutic product candidate based on Alfacell’s proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.”

SOURCE: myMeso › Alfacell moving forward with ONCONASE while feeling financial pinch

Because of its long latency period – from 20 up to 50 years – mesothelioma usually occurs in older people, age 50 and older. For that reason, Carlisle’s mesothelioma eluded diagnosis early on, with doctors mistaking her symptoms for ailments such as irritable bowel syndrome (IBS), pelvic infection and endometriosis. Doctors were stunned when they diagnosed peritoneal mesothelioma.

Because of her young age, researchers believe Carlisle may have come in contact with asbestos – the only known cause of mesothelioma – in her school, or possibly from a factory yard near her childhood home, which she used as a shortcut on her way to school each day. Asbestos sheets were cut at the yard.

According to the report, about 2,000 people in Britain die from mesothelioma each year, a figure that has doubled since 1992. The paper reports that 90,000 people in the UK will die from the disease, and another 90,000 from other asbestos-related lung diseases.

Additionally, the report says about 200 school workers have died or are suffering from illnesses related to asbestos exposure in schools in Britain, where it is estimated that about 13,000 schools still contain asbestos.

Following her diagnosis, Carlisle worked for mesothelioma and asbestos awareness. Her family requests that donations in her memory be made to the Oldham Cancer Support Centre in Failsworth:

Oldham Cancer Support Centre
Failsworth Primary Care Centre
Ashton Road West
Failsworth
M35 0AD
Tel: 0161 906 2940

SOURCE: myMeso › UK’s youngest meso victim passes away

A British record label, Candid Records, agreed to release the CD, and Keith recruited a number of musicians to fill in the gaps on the tracks to finally see the project through. The CD was called Free Time, a name initally selected because the original tracks recorded in 1973-74 were done during a recording studio’s down time, when a friend who worked there was able to lend Keith and Gary the space. But the liner notes, penned by Keith to tell the story of how the recording came together, tend to more solemn reflection.

“Then suddenly completion is in front of you and there is no free time anymore,” he writes, and it’s easy to see the dual implication of a completed project and a completed life.

Keith passed away just as the CD was pressed, and it is unlikely he saw it in its final form.

The special edition release of Free Time is available only through the Candid Records web site, and is shipped from the UK. Cost is £9.99 plus shipping, which totals around $24 U.S. once you figure in the exchange rate. But all proceeds from the sales will go to Bart’s Mesothelioma Research, an organization in Britain dedicated to the treatment of mesothelioma.

I received my CD yesterday. Full of free-spirited modern jazz tunes highlighting Keith on saxophone, the CD is joyful and jamming and sometimes poignant. It is perhaps hardest to comprehend when mesothelioma steals the breath of those who create music, before it steals their life.

SOURCE: myMeso › jazz CD a tribute to artist affected by meso

Shadwick, who passed away from mesothelioma on July 28, 2008, was a respected journalist and author whose background as a jazz and rock musician in the 1970s led to a career focus on music and musicians. His credits include books on noted jazz musician Bill Evans, as well as Jimi Hendrix and Led Zeppelin. He also authored The Jazz & Blues Encyclopedia, the Guinness Guide to Classical Composers, and edited The Gramophone Good CD Guide. Additionally, he was a regular contributor to publications including Jazzwise magazine, The Independent and The Daily Mail.

According to an article published on All About Jazz.com, during his early 20s, Shadwick was a jazz and jazz/rock musician, playing saxophone, flute and piano. He was a founding member of the Sydney, Australia-based group, Sun, which released one self-titled album in 1972 before splitting up. In 1973 and 1974, the story reports, Shadwick and fellow Sun member, drummer Gary Norwell, recorded some jazz tracks with fellow musicians Justin McCoy and Robert Luckey when local Point Five Studio offered them use of its facility during a free downtime.

As a nod to their luck in securing the studio, the musicians named the album Free Time, but it was not completed or released. Shadwick held onto the tapes, and revived work on the recording in 1984, with guitarist Billy Jenkins, and again in 2005, with guitarist Mike Wollenberg.

All About Jazz notes that Shadwick was motivated to finish the album in 2005, when he was diagnosed with mesothelioma, and completed the project in 2007, although it is unlikely that he lived long enough to see its official pressing, which was delivered to his home right around the time of his death. The album was produced and released by Candid Records in the UK.

The Special Edition of the Free Time CD is available in limited release through the Candid Records web site, with all proceeds benefitting Bart’s Mesothelioma Research. Cost is £9.99 plus shipping, which totals around $24 U.S.

SOURCE: myMeso › Shadwick CD benefits mesothelioma research

According to recent report in the Seattle Post-Intelligencer, there were 20 experts appointed to the SAB’s asbestos panel, charged with evaluating the validity of the EPA’s plan to change how the toxicity of the six types of asbestos regulated by the government differ in danger. Its findings would be submitted to the White House Office of Management and Budget (OMB).

According to the PI report, scientific advisors say the EPA used the asbestos panel to submit new studies that contradict longstanding research into the dangers of asbestos. The new studies say chrysolite, in particular, the most common type of asbestos, isn’t dangerous and doesn’t cause mesothelioma.

PI quotes Dr. David Egilman, an occupational medicine specialist, who testified at the public meeting, as saying the new study was financed by mining and other asbestos-related industries, and said the studies have no scientific credibility.

Another vocal spokesperson at the hearing was Sen. Patty Murray, who sponsored S. 742, the Ban Asbestos in America Act of 2007, which passed the Senate on Oct. 4, 2007. Currently, it is the companion bill to H.R. 3339, the Bruce Vento Ban Asbestos and Prevent Mesothelioma Act, sponsored by Rep. Betty McCollum, which currently is in committee in the House of Representatives.

Sen. Murray has long been an advocate for a total asbestos ban, calling for better worker protection. The PI quotes Sen. Murray as telling the committee, “I’d like the political appointees at the EPA to look into the eyes of a mesothelioma patient and say that asbestos isn’t dangerous. It appears that this administration is once again putting politics before public health.” Murray is currently chairwoman of the Senate Employment and Workplace Safety Subcommittee.

The EPA asserts the new system is needed to improve how asbestos-contaminated Superfund sites are evaluated. The organization can move forward with its proposal without approval from the OMB or the SAB, if it so chooses.

SOURCE: myMeso › Why is EPA proposing relaxed asbestos rules?

According to the report, the study evaluated a regimen of Navelbine (vinorelbine) and Platinol (cisplatin) for the treatment of 54 patients with newly diagnosed non-resectable mesothelioma. The median number of cycles of chemotherapy administered was four. There were two complete responses and 14 partial responses.

The median survival was 16.8 months, and the median time to tumor progression was 7.2 months. The one-year survival was 61 percent, the two-year survival was 31 percent, and the three-year survival was 4 percent.

The authors of the study say these results are as good as or better than currently used combinations for treatment of mesothelioma.

SOURCE: myMeso › Chemo combo highly effective for mesothelioma

The bill is currently in committee, with the House Committee on Energy and Commerce. Even if your district’s representative is not on this committee, it is important to let him or her know that you support the bill so that they know how to vote. The more voices they hear from their constituency, the better chance they will pay attention when this finally comes to the House floor.

If your representative IS a member of this committee, it is even more important. Many bills “die” in committee, never making it to a vote of the full House or Senate. Please make sure your representative helps get this bill approved in committee and to the floor for its vote.

My representative, Terry Everett (2nd District, Alabama), acknowledged his receipt of my request with a letter, in which he said he will keep my thoughts in mind should the bill make it to the floor, although he is not a member of the Committee on Energy and Commerce.

According to information provided by Everett’s office, H.R. 3339 would require several actions to be taken by the federal government in addressing asbestos and its harmful effects. The Environmental Protection Agency (EPA) would establish a plan to increase awareness of the dangers posed by asbestos-containing materials in homes and workplaces and encourage participation in research and treatment endeavors of asbestos-related disease patients.

The bill also would require the disposal of asbestos-containing materials within two years and the prohibition on the importing, manufacturing, processing or distributing of asbestos-containing materials, except for specific exemptions sought by the Department of Defense and National Aeronautics and Space Administration.

If you are not sure of the representative for your Congressional District, visit the House of Representatives online. You can also find out here if your representative is a member of the House Committee on Energy and Commerce.

Please take the time to do this today. Your one voice is SO important. Let it join thousands of others to finally make a real difference.

SOURCE: myMeso › Asbestos, mesothelioma bill still in committee

Although Coady didn’t suffer from mesothelioma, he was very much aware of the risks posed by asbestos. His work during his time in the Navy very often put him in contact with the substance, he said, and seven of his friends died from mesothelioma since his retirement. In addition, for 10 years following his retirement, Coady worked as president of the Navy Mutual Aid Association, a non-profit veterans benefit group and life insurance service, where he said he saw what he thought was a disproportionate amount of lung cancer deaths.

When he began investigating lung cancer research efforts, Adm. Coady was shocked at the relatively few dollars spent by the Veterans Administration and the U.S. Department of Defense, considering the number of veterans affected by the disease. He also was disappointed at the overall lack of funding for lung cancer research in comparison to spending on other cancers, especially since lung cancer is the leading cancer killer.

He dedicated himself as Chairman of the Board for the Lung Cancer Alliance, fighting the battle for lung cancer awareness and funding under the organization’s motto “No More Excuses. No More Lung Cancer.” He led efforts in lobbying Congress to make lung cancer a national health priority.

Just last week, Coady saw some of the first fruits of his efforts, when Senators Dianne Feinstein (D-CA) and Chuck Hagel (R-NE) introduced legislation in the U.S. Senate creating and authorizing at least $75 million for lung cancer research. This is the first ever multi-agency, comprehensive program targeted at reducing lung cancer mortality.

Perhaps the best memoriam Adm. Coady could receive is for supporters of lung cancer awareness and research to contact their U.S. Senators NOW and ask them to add their support to S. 3187, the Lung Cancer Mortality Reduction Act. Remember him and take action for those to come after him! You can view his obituary here.

Blessings to Adm. Coady’s family at this time of loss.

SOURCE: myMeso › LCA Chairman Coady has died

When her grandfather passed away, 9-year-old Lexi, who lives just outside Allentown, Pennsylvania, channeled her grief into a letter-writing campaign, hoping to raise awareness of mesothelioma. According to an article in The Morning Call, a publication that serves Pennsylvania’s Lehigh Valley, Lexi wrote medical research organizations, political leaders including President George Bush, and even television celebrities like Oprah Winfrey, hoping to spread the word about asbestos danger and mesothelioma.

This year, the Meso Foundation invited Lexi to give the keynote address Friday, June 27, at its International Symposium. The Morning Call quotes Chris Hahn, the foundation’s executive director, as saying, ”We wanted to show the full spectrum of the disease’s effect on families. How inspiring it is that this young gal going into eighth grade has this concern for a much bigger national problem.”

SOURCE: myMeso › Girl honors grandpa at Mesothelioma symposium

Senators Feinstein and Hagel were instrumental in authoring a policy resolution in 2007 to designate lung cancer as a public health priority, which was passed unanimously. The resolution called for research, better treatments, and early detection, with a goal of reducing lung cancer mortality by 50 percent by 2015.

This new bill would establish that comprehensive program under law and authorize funding, according to a release from the Lung Cancer Alliance, which today issued a call to action for its support.

“We have seen great advancements in prostate and breast cancer survival rates and we must commit ourselves to making the same progress with lung cancer,” Sen. Hagel said, noting that lung cancer currently accounts for 28 percent of all cancer deaths in the United States.

Each year, lung cancer kills more people than breast, prostate, colon, kidney, melanoma and liver cancer, combined.

Senator Feinstein said, “It’s time for the federal government to step up its efforts and make fighting lung cancer a national priority.”

Contact your Senator TODAY!

SOURCE: myMeso › Senate introduces lung cancer legislation

Some of you who are following Debbie on her journal have already heard the good news – on June 20, she learned that her tumor (which she wittily nicknamed Theo) has shrunk by 10 percent after the first of three scheduled chemoembolization treatments. She had her first treatment May 20, and the second June 20, when she learned Theo had gotten smaller.

According to www.radiologyinfo.org, chemoembolization is a combination of chemotherapy and a procedure called embolization to treat cancer, most often of the liver. According to the web site, catheter embolization is the deliberate introduction of foreign (“embolic”) material such as gelatin sponge or metal coils to stop bleeding or cut off blood flowing to a tumor or arteriovenous malformation.

Debbie traveled to Frankfurt, Germany, to have the procedure, which is still a trial, done by Dr. Thomas J. Vogl, Chairman, Department of Radiology, Department of Diagnostic and Interventional Radiology – University Hospital, Johann Wolfgang Goethe, University of Frankfurt am Main.

In this procedure, Dr. Vogl catheterizes the tumor and administers localized chemotherapy directly into the arteries feeding the tumor. Once the chemotherapy has been administered, other agents can be administered to block off the blood supply to the tumor.

Debbie’s description of the procedure is a little more colorful:

“A small incision will be made to expose the artery that feeds the tumour which is in the femour. A catheter is inserted and pushed up into the area affected. Embolization is a glue like substance which is put in to seal off the tumour and the chemo is then added and the whole area sealed off. The chemo is left to do its job. It is something like having a room with 2 doors, sealing off the back door and throwing in an explosive and sealing up the front door.”

One of the strangest things? The clinic where Debbie visits Dr. Vogl for these treatments is located on a street of the same name as her tumor’s nickname! Theodore Stern Kia 7. Visit Debbie’s blog to read all about her experiences with Dr. Vogl and this treatment. She even has photos of herself at the clinic.

Debbie points out that chemoembolization is not a cure for mesothelioma, but is thought to slow the growth of the tumor or reduce it, allowing the patient a longer life.

In conjunction with or following this treatment, Debbie will undergo a dendritic cell vaccine. According to the web site drugresearcher.com, dendritic cells – a part of the body’s immune system that detects foreign proteins in the body – can be used as vaccines by mixing them with genetic material from the patient’s tumour and infusing the treated cells back into the patient. The dendritic cells present the tumour antigens to the body’s white blood cells (T lymphocytes) for destruction.

SOURCE: myMeso › Debbie’s mesothelioma tumor shrinks!

The Libby program, dubbed the Libby Amphibole Health Risk Initiative, is funded by the Environmental Protection Agency and the Department of Health and Human Services’ Agency for Toxic Substances and Disease Registry. The study is expected to span 5 years with a goal of expanding knowledge about the potential and real health issues of asbestos exposure.

Libby already has proved a tragically rich source of knowledge about long-term exposure to high levels of asbestos, as the EPA’s initial examination and cleanup of the town focused on miners with direct exposure to the substance in their jobs, as well as people who handled asbestos mineral and were exposed to asbestos dust secondarily on a daily basis.

But, the Gazette reports, too little is know about exposure to lower levels of asbestos. EPA officials hope that results of the study will benefit not only the residents of Libby, but people throughout the country.

In April, the Minnesota state legislature approved $4.9 million for its own five-year study, to be conducted under the direction of the University of Minnesota, in connection with unusually high levels of mesothelioma affecting Iron Range mine workers. A large question in the area is whether dust from the taconite mined there – a fibrous mineral similar to asbestos – could also cause mesothelioma.

A key part of the Minnesota research will be an examination of previous asbestos exposure among mine workers, which will expand the base of knowledge about the affect of asbestos on health, in addition to the new studies about the effect of taconite.

According to the Billings Gazette, among tests to be included in the Libby study are a comparison of film and digital chest X-rays to determine which is best for assessing the lungs, a comparison of the health of people exposed to Libby asbestos in childhood versus people who weren’t, an expanded evaluation of Libby residents who were exposed to asbestos, an assessment of whether the health problems related to asbestos exposure extend beyond lung disease.

Researchers in Libby also hope to make improvements to public health tracking systems and patient health record databases, to better link exposure information to health conditions, the Gazette reports.

Gayla Benefield, perhaps one of the best-known residents of Libby for her early outcry about the health effects of asbestos on the people in her town, says she is happy to see an emphasis on research.

She was a charter member of the board of directors of the Center for Asbestos Related Disease (CARD), a not-for-profit clinic governed by a volunteer community board and devoted to healthcare, outreach, and research to benefit all people impacted by exposure to Libby amphibole asbestos. She only recently retired from her position with that organization.

“This is something I’ve wanted from the onset – more study and more research,” she says. “I’ve been especially interested in how much or how little of the (asbestos) fiber can cause meso, and I’ve been really concerned about the schools having been contaminated.”

The key, Benefield says, is to detect mesothelioma at its earliest stage, when there is still time for treatment to prolong life. When people around her in Libby began being diagnosed, she says, their mesothelioma was so advanced that many died within days of the diagnosis.

“We all – everyone in Libby – live under the threat of developing mesothelioma,” she says. “They’re never going to get all that (asbestos) fiber out of Libby, or anywhere for that matter, homes with asbestos insulation, so the research is the big thing. Any and all research having to do with mesothelioma is fantastic. A dream come true.”

SOURCE: myMeso › $8 million asbestos study in Libby

A special focus of this year’s conference was lung cancer, which is the leading cause of cancer deaths in the United States. Mesothelioma affects the lining of the lungs, and may also affect the abdomen or the pericardium (the sac around the heart).

There was a great deal of hope for a new drug, Erbitux, which doctors hoped would prove to have significant results in prolonging survival for lung cancer patients (it didn’t), as well as review of a currently popular lung cancer drug, Avastin, which in its Phase III trial was shown to help keep the disease from progressing.

But among the reports of facts and figures and products and treatments, was a report by Robert Bazell at MSNBC.com. Why, he wondered, are we not further along in the War on Cancer, which was declared as a national health priority in 1971, when President Richard Nixon signed the National Cancer Act.

The Act, Bazell points out, created the National Cancer Institute as a separate entity from the National Institutes of Health, with a dedicated budget for curing cancer. The NCI started with $230 million per year, and now has a budget of $5 billion.

Certainly, progress has been made, and there have been steady declines in breast, colon and prostate cancers, most due to better methods for early detection, Bazell points out. But, overall, he says, the death toll from cancer has declined only 5 percent between 1950 and 2005. FIVE percent!

What are the challenges? Why are we not winning this war?

Certainly, the nature of cancer itself has something to do with it – there are more than 200 diseases that fit into the definition of “cancer,” uncontrolled cell growth, he points out. And, even though funding has increased, if you adjust that $5 billion budget for inflation, spending on cancer research has actually been falling in recent years, he says.

But I was intrigued by his most compelling argument, which seems so simple. He notes that “it would be very useful to have a discussion on how much we spend on BASIC RESEARCH and PREVENTION, compared to how much we spend on marginally useful treatments.”

Is it possible that we can no longer see the forest for the trees?

SOURCE: myMeso › Why haven’t we won the war?

According to the Duluth News Tribune, the news of the latest mesothelioma diagnosis was discovered as the result of a comparison study done by the Minnesota Department of Health, comparing 72,000 Iron Range miners against the Minnesota Cancer Surveillance System, which is the state’s cancer registry. The paper reports Health Department spokesperson Buddy Ferguson was unable to provide details about the 59th miner diagnosed, including whether or not this case of mesothelioma had resulted in an additional death.

A focus of the five-year study, which is under the direction of the University of Minnesota’s School of Public Health, is to determine if there is a relationship between mesothelioma and the dust from taconite mining that is a central part of the Iron Range mine operation. Currently, mesothelioma is known only to be linked to asbestos. Because of the long latency period of the disease, usually between 20 and 50 years, it is uncertain whether the mesothelioma cases could be caused by previous asbestos exposure on the part of affected individuals, or taconite dust, or both.

Minnesota Public Radio reported in June 2007 that the Department of Health had conducted a study in 2003 when it found 17 cases of mesothelioma among Iron Range workers, and determined that 14 of the 17 cases had previous exposure to asbestos as well as taconite dust. Between 2003 and 2007, an additional 35 miners were diagnosed with mesothelioma.

According to WDIO-DT and WIRT-DT, ABC affiliates channels 10 and 13 serving the Northland area, approximately 1,200 current and former Iron Range miners will undergo random respiratory and health screenings, beginning next summer, as part of the study. The station reports that this summer researchers will begin analyzing old health studies, and doctors will examine current asbestos exposure controls.

The research study group has been named the Taconite Workers Lung Health Partnership. Read more about the project at its web site.

SOURCE: myMeso › Mesothelioma claims 59th Iron Range miner

I’ve posted about John several times on this site. He was selected by the readers of Golf Digest magazine to participate in this first-ever celebrity foursome event. Diagnosed with Stage IV lung cancer, John used the event as a chance to raise awareness about lung cancer and to inspire those with the diagnosis to keep meeting the challenges of everyday life, and taking advantage of life’s unique opportunities.

This morning, Matt Lauer interviewed John and his brother, Kevin, who caddied for his big brother on the last hole in an emotional show of support. Watch the video at MSNBC.com.

In addition to this video, the Lung Cancer Alliance has the first part of what will be a multi-part documentary about John’s battle against Lung Cancer up on its site. John is a spokesperson for the organization. Watch the first episode at the LCA web site.

John has made it his mission to raise awareness about lung cancer, with the hopes of increasing funding for research and treatment. His campaign gives hope to everyone who battles lung cancer in its many forms, including those fighting mesothelioma, which affects the lining of the lungs. Thank you, John, for your willingness to go that extra mile!

SOURCE: myMeso › Atkinson conquers U.S. Open course

Minnesota Public Radio reports that researchers and politicians will meet today to discuss progress in establishing the study. According to the report, the University of Minnesota School of Public Health is assessing the health of active and retired miners, reviewing death certificates, and delving into the 58 deaths from mesothelioma. The Natural Resources Research Institute is analyzing iron ore samples and dust in the air in Iron Range communities, to see how closely they match asbestos dust, says MPR.

According to the Iron Mining Association of Minnesota web site, the industry’s six iron mining and processing operations produce two-thirds of the iron ore used to make steel in the United States. Combined, they represent a $4 billion capital investment and employ nearly 4,000 men and women. These companies contribute over $1.5 billion each year to the state’s economy in the form of purchases, wages and benefits, royalties and taxes.These companies contribute over $1.5 billion each year to the state’s economy in the form of purchases, wages and benefits, royalties and taxes.

Taconite is an extremely hard rock that contains about 25 percent iron, according to an IMA fact sheet. It is found on the Mesabi Range in northeastern Minnesota, which extends 110 miles in a southwesterly direction. After World War II, when natural high-quality iron ore deposits were beginning to be depleted, two companies began making major investments in taconite, and began producing pellets in 1956 and 1957, and a decade later taconite was in production in all of the area’s six mines.

To date, Minnesota mines have produced more than 1.2 billion tons of taconite pellets, IMA reports.

Information about taconite on the Minnesota Department of Natural Resources web site says “taconite saved Minnesota’s iron ore mining industry.”

How heartbreaking that Minnesotans are only now finding out the cost.

SOURCE: myMeso › Minnesota examines taconite meso danger

The article, which studied the cost of care for elderly cancer patients in the United States, used Surveillance, Epidemiology, and End Results-Medicare files to identify 718,907 cancer patients and 1,623,651 noncancer control subjects. Researchers estimated net costs of care for elderly cancer patients for the 18 most prevalent cancers and for all other tumor sites combined.

The study reports that costs of care were estimated for each phase by use of Medicare claims data from January 1, 1999 through December 31, 2003. They found that costs to Medicare were highest for lung, colorectal and prostate cancers.

An article in HealthDay News examining this latest report says study co-author Robin Yabroff attributes rising costs to a growing population of seniors in the U.S., as well as the inclusion of more prescription drugs in Medicare coverage. Yabroff is an epidemiologist at the U.S. NCI.

The report states that the number of patients receiving chemotherapy for lung, colorectal and breast cancer rose from 1991 to 2002, and that those increasing costs do not even reflect many of the newest, most expensive drugs now in use.

The HealthDay report quotes Dr. Len Lichtenfeld, deupty chief medical officer at the American Cancer Society, as saying that “the impact to Medicare is going to be substantial.” He goes on to say that the increasing costs for new drugs may actually prevent some patients from getting the treatment they need. Even if the drug is covered by Medicare, he says, the cost of the patient’s co-pay may be too high for them to afford it.

SOURCE: myMeso › Cancer treatment costs rise, affect Medicare

According to the company’s news release, available in its entirety on the Mesothelioma Applied Research Foundation web site, the trial is moving forward after a favorable review of currently available safety and efficacy data from the Phase II portion of the study. This is an international study, expected to enroll 660 patients with testing centers in the United States, Belgium, Germany, the Netherlands, New Zealand, Spain, Sweden and the United Kingdom. It will be an ongoing randomized, double-blind, placebo-controlled trial.

Information provided by Merck says the trial will examine the safety, tolerability and anti-tumor activity of oral vorinostat with best supportive care as compared to best supportive care plus placebo in patients with advanced mesothelioma who have failed or are intolerant to prior chemotherapy, icnlucing pemetrexed in combination with either cisplatin or carboplatin.

Primary endpoints of the Phase III trial include overall survival as well as characterization of the overall safety and toxicity of vorinostat in patients with advanced malignant mesothelioma.

Patients interested in more information about the trial and how to enroll should call toll-free 1-866-890-6619 (in the U.S.) and 1-888-577-8839 (outside the U.S.) or visit the Merck Cancer Trials web site.

Zolinza is currently approved in the U.S. for treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recrruent disease on or following two systemic therapies.

SOURCE: myMeso › Merck begins vorinostat Phase III meso trial

He arrived in California yesterday for a practice round, and will tee off with the celebrities in front of 250 spectators, along with camera crews and journalists, tomorrow. His final round and his score will be televised on June 15 as part of the lead-in to the U.S. Open coverage. The special will feature clips from the 18 holes of golf. John vows to break 100 on the tough course, with a goal of shooting an 89.

You can still sign up to sponsor John as part of his U.S. Open adventure, with funds going to lung cancer research and awareness. He is encouraging people to agree to double their pledge if he makes his goal of breaking 100. Find a sponsor form at the Lung Cancer Alliance web site. GO JOHN!

SOURCE: myMeso › Quick update on Atkinson

Of course, on Monday this week, it was announced and reported here that Onconase had failed the primary objective of its late-stage trial. This news was particularly disappointing since the drug already has orphan drug status in the U.S., Europe and Australia due to the very high hopes for its success. Despite failing in its primary objective, however, testing did show that the drug is effective in a secondary effect, helping to prolong the life of those treated after standard chemotherapy has failed.

The report of Onconase’s initial failure prompted WTN’s Clark to revisit Quintessence to find out if the Onconase failure would derail the development of their QBI-139. In his new report, Clarks says he found researchers undaunted and pressing forward. He says they hope to move the drug into clinical trials sometime this summer, and they believe the success of Onconase’s secondary role and hopeful FDA approval in that area will help pave the way for general acceptance of RNase cancer therapies.

In his earlier report, Clark pointed out that QBI-139 has several differences from Onconase in the way it is produced, which he believes will make it inherently more effective than Onconase.

He points out that mesothelioma is a particularly difficult cancer to treat, and wonders if the selection of mesothelioma as a research track by Alfacell was made to help fast-track the development of the drug. Perhaps, he wonders, the drug might be more effective on “more common and easier to treat cancers than mesothelioma.”

SOURCE: myMeso › Quintessence continues with mesothelioma drug

Today there was a great article in the Detroit Free Press about Atkinson. The article states that Atkinson considers his “Achilles heel” in the competition to be the fact that he’s never played the tough Torrey Pines U.S. Open course, not that he has lung cancer. The avid golfer was on the links shortly after his diagnosis (he shot a 78) and walked the course after completing four rounds of chemotherapy. His goal for the celebrity tournament is to break 100.

You can also keep an eye out for Atkinson on NBC Nightly News tomorrow, June 5. He is scheduled to appear, barring any unexpected national events that bump him from the slot.

Atkinson will be teamed with celebrities Justin Timberlake, NBC Today Show anchor Matt Lauer, and Dallas Cowboy star Tony Romo in the tournment, which will be aired on NBC Sports at 2 p.m. ET June 15.

How wonderful that Atkinson has this chance in the spotlight to talk about lung cancer, and to promote efforts to increase funding for research and to raise awareness. He also is an official spokesman for the Lung Cancer Alliance.

SOURCE: myMeso › Atkinson in the news again

John Atkinson talks about U.S. Open plans with ESPN2.

Atkinson will play the tough Torrey Pines course in San Diego. While on the radio program, John shares the story of his diagnosis and battle with lung cancer, and his plans to break 100 in the tournament.

John is a spokesperson for the Lung Cancer Alliance. Visit their web site to download a sponsor form, and consider hosting a party on the day of the celebrity tournament. John is encouraging donors to vow to double their pledge if he breaks 100.

Let’s get behind this remarkable man, who has a unique opportunity to share the message of the importance of lung cancer research and funding. NBC Sports will broadcast the celebrity event from 2-3 p.m. ET.

SOURCE: myMeso › Atkinson talks to ESPN2 about U.S. Open

According to Rob Grayson, director of marketing for the Meso Foundation, the event actually started as a purely scientific event, geared toward researchers and scientists, with technical presentations. However, at the time, there were no informational or educational events like it, and they found that patients, families and caregivers wanted to attend.

“Initially, these people would come and sit in on these high-level presentations by scientists, with very technical presentations. We saw the interest and our meeting has now evolved into more of a patient meeting, the scientists speak in more layman’s terms, and we’ve added programs to reach out to people who are also interested in the community of support and the activism that takes place,” Grayson said.

The advocacy element is a new piece of the symposium, added last year when the meeting coincided with debate in the Senate on the Ban Asbestos in America Act, S. 742, sponsored by Senator Patty Murray (D-WA).

“The day we lobbied, they took an administrative vote, and it passed in the Senate. So we’re going back to Washington this year,” Grayson said.

Advocacy efforts this year will include a rallying cry to the House of Representatives to move quickly to pass the legislation in the House, which bans asbestos and provides research funding for mesothelioma. Last week, the Foundation issued an action alert in support of The Bruce Vento Ban Asbestos and Prevent Mesothelioma Act of 2007 (H.R. 3339), the companion to the Senate bill. The bill includes $10 million for mesothelioma research.

“Normally we’d hold the Symposium in a different city each year, but it’s almost the same timing as last year, with the bill pending, this time in the House, so we’re back to Washington,” Grayson explained.

Those attending the Symposium can register to participate in the advocacy efforts, and the Meso Foundation will arrange for them to meet personally with their congressional delegate, and will provide a training session to help advocates prepare for the meeting.

In addition to lobbying for passage of the House bill, Symposium advocates will request that the Senate’s Defense Appropriations Subcommittee maintain, for the second year, mesothelioma’s eligibility to compete for medical research funding from the Department of Defense. In 2007, the DoD appropriated $50 million and included mesothelioma as a research priority for its Peer Reviewed Medical Research Program, effective in the 2008 budget. The Meso Foundation is working for continuing and increasing funds for mesothelioma research in the 2009 defense appropriations bill.

“There currently is no ban on asbestos, so companies can use it however they see fit. We’ve pretty much stopped mining here, but asbestos is still used in about 3,000 products that you could go out and buy right now. Even if we banned asbestos tomorrow, it probably won’t change the rate of sickness for the next 50 years, due to the latency period of asbestos. That’s why the funding for research is so important,” Grayson says. “Advocacy and the call for a ban on asbestos raises awareness, and raises money for research, which is what we need to deal with the illness itself,” he said.

In addition to advocacy, the Symposium again will feature an educational program, with sessions covering topics including Peritoneal Mesothelioma, Pleural Meso Surgical Options, Emerging Therapies, Optimizing Patient Care, and Scientific Advances in Meso Research. Other educational programs will provide instruction on outreach topics including volunteerism, fundraising, peer support and advocacy, to help those who want to make a difference learn how to be most effective.

A Gala Dinner will honor those people living with meso, and recognize outstanding volunteers and advocates for their hard work and dedication to raising awareness. The dinner will feature a unique guest speaker – Seventh grader Lexi Miletto, the granddaughter of Joseph Miletto, who died in 2005 of peritoneal mesothelioma.

Scholarships for Symposium registration fees, as well as for transportation and accommodations, are still available for patients, family members and caregivers who would like to attend. Contact the Meso Foundation at www.curemeso.org or call 805-563-8400 for details.

The Mesothelioma Foundation was started in 1999, by attorney Roger Worthington. Unfortunately, Grayson says, there was an initial stigma because of his association, with people suspicious the Foundation was attempting to gather clients for his firm, so he removed himself from the Board of Directors and the Foundation was re-established as a non-profit, 501(c)3 organization. Today, with 8 staff members, the organization raises $2.5 million annually and funds more than $1 million in research projects.

“Currently, most of our funding goes to seed money to help researchers who have good ideas for treatment to validate their work, and take it to the NIH to get additional funding for the next step of the research,” Grayson explained. “We hope very soon that we’ll be able to fund clinical trials.”

SOURCE: myMeso › MARF announces Mesothelioma Symposium

Complementary medicine is used along with standard medicine, while alternative medicine is used in place of standard treatments.

Complementary and alternative medicine may include dietary supplements, megadose vitamins, herbal preparations, special teas, acupuncture, massage therapy, magnet therapy, spiritual healing, and meditation.

Not long ago, I shared Charlene Kaforey’s good news, when she discovered her mesothelioma mass had diminished by half after completing a first round of cancer vaccines, considered an alternative treatment.

Recent news has included reports of research ranging from the effects of nonsteroidal anti-inflammatory medicines in combination with chemotherapy, to the use of Chinese mushrooms in homeopathic treatment, to a study indicating traditional chemotherapy might enhance the effectiveness of cancer vaccines, which are currently in clinical trials.

The problem, according to complementary medicine (CM) professor Edzard Ernst, in an editorial published recently in BMJ Clinical Evidence, is that “one side of the debate argues that there is no scientific evidence that can support CM, while the other side believes scientific evidence cannot be applied to CM.”

The danger, he says, is that waiting for absolute evidence might prevent someone from trying a therapy that could be beneficial, but siding with the idea that CAM simply cannot be proven may lead a patient into treatment that could cause more harm than good.

The National Cancer Institute’s Office of Complementary and Alternative Medicine (OCCAM), which coordinates the Institute’s research program in CAM, has established a goal of evaluating data from CAM practitioners with the same rigorous scientific methods employed in evaluating treatment responses with conventional medicine.

Major categories of CAM therapies, as determined by OCCAM, include alternative medical systems (built upon complete systems of theory and practice, like traditional Chinese medicine or homeopathy), energy and electromagnetic based therapies, exercise therapies (like yoga), manipulative and body-based methods, mind-body interventions (like hypnotherapy), nutritional therapeutics, pharmacological and biologic treatments (like vaccines), and spiritual therapies (healing, prayer).

OCCAM is developing the NCI Best Case Series (BCS) program based on its evaluations of CAM therapies, in which it provides an independent review of medical records and medical imaging from patients treated with unconventional cancer therapies.

But whether or not alternative and complementary medicine can be proven effective, people will still seek it out, says Professor Ernst. The “almost insatiable hunger of patients” for CM has driven its importance, he says, despite criticisms, praise or skepticism from the medical community, scientists or politicians, and in spite of the fact that more often than not health insurance does not cover the treatments.

Obviously, this topic – and its accompanying debate – needs much more examination. I will be exploring it more in the future. Do you have an experience with complementary or alternative medicine? Share it with us!

SOURCE: myMeso › Complementary, alternative medicine debate

This week, according to a report by the Canadian HR Reporter, the Canadian Labour Congress is calling for a ban on the mining, and a financial support plan for the approximately 700 miners who would be affected by the industry closure.

The call for the ban comes despite delays in making public the results of a scientific study examining the health risks of asbestos. According to CBCNews.ca, “Michel Arsenault, president of the Quebec Federation of Labour, in February convinced his colleagues at the Canadian Labour Congress not to call for a ban on asbestos mining until after the study was completed and made public.”

The study, conducted under the direction of Health Canada, was begun last November by a team of seven scientific and medical experts. According to CBC, the report was completed in March and promised to be released in weeks. Experts who worked on the project are objecting to the delay in releasing the report.

CBC quotes Leslie Staynor, head of the School of Public Health at the University of Illinois, who worked on the study, as saying, “I want to make the record clear that nothing in the report would argue against the sensibility of an asbestos ban in Canada or for that matter anywhere else in the world.”

The CBC report points out that asbestos has been called a “deadly threat” by the International Labour Organization, the World Health Organization, the International Association for Cancer Research and many more health agencies.

SOURCE: myMeso › Canadian labor group supports asbestos ban

Most people are familiar with the nonsteroidal anti-inflammatory drug naproxen, which is found in their common pain relievers like Aleve.

Wikipedia defines a nonsteroidal anti-inflammatory drug as “drugs with analgesic, antipyretic and, in higher doses, anti-inflammatory effects – they reduce pain, fever and inflammation. The term “non-steroidal” is used to distinguish these drugs from steroids, which (among a broad range of other effects) have a similar eicosanoid-depressing, anti-inflammatory action. As analgesics, NSAIDs are unusual in that they are non-narcotic. The most prominent members of this group of drugs are aspirin, ibuprofen, and naproxen partly because they are available over-the-counter in many areas.”

The NSAID used in this study is piroxicam.

The study used two mesothelioma cell lines, and explored the effects of piroxicam alone, as well as in conjunction with CDDP. The report says that “treatment with piroxicam or CDDP alone altered the cell cycle phase distribution as well as the expression of some cell cycle regulatory proteins in both cell lines” and that “these effects were increased, even if in a not completely overlapping manner, after treatment with the association of piroxicam and CDDP.”

The report notes that “the mechanisms through which NSAIDs regulate the cell cycle as well as the signal pathways involved in the growth inhibition, remain unclear” but says the findings from this recent study “hold promise in the treatment of mesothelioma.”

The study was orginally published in the Journal of Transitional Medicine.

SOURCE: myMeso › New mesothelioma treatment research promising

This was the fourth time Jordan battled cancer. In the 1980s, he was diagnosed with leukemia lymphoma. About 10 years later, he was diagnosed with prostate cancer. He also had two battles with skin cancer. In 2000, Jordan wrote a book about his experience with cancer, titled “No Such Thing as a Bad Day,” which provided inspiration to cancer survivors.

He and his wife, Dorothy, founded Camp Sunshine, a nonprofit camp for children with cancer, and Camp Kudzu, a nonprofit camp for children with Type 1 diabetes. Jordan also founded the Georgia Cancer Coalition, a $1 billion organization funded by tobacco settlement money.

The Atlanta Journal-Constitution has published the following statement from Jordan’s family:

The Jordan Family greatly appreciates the overwhelming amount of love and support we have received from our friends during the many difficult years of Hamilton’s illness. We are saddened beyond words at his death, but we are also at peace knowing that he is finally comfortable after years of fighting an incurable disease. A truly unforgettable person, Hamilton will be remembered as a compassionate, brilliant, and selfless human being who touched so many lives with his limitless generosity.

In lieu of flowers the family asks that your donations be sent to any of the following charitable organizations:

The Hamilton Jordan Mesothelioma Research Fund at the University of Maryland-Baltimore Foundation, University of Maryland Greenebaum Cancer Center, 100 North Green Street, Suite 600, Baltimore MD 21201

Camp Sunshine, 1850 Clairmont Road, Decatur, GA 30033, enriching the lives of children with cancer through recreational, educational and support programs throughout the year

Camp Kudzu, 4279 Roswell Road, Suite 102, Box 254, Atlanta, GA 30342, providing education, recreation and peer-networking programs for children with diabetes

Community Advanced Practice Nurses, Inc., 173 Boulevard NE Atlanta GA 30312, offering free mental and physical healthcare to the homeless and medically underserved.

A memorial service for Hamilton Jordan, White House chief of staff during the Carter administration, will be held with family and close friends at 2 p.m. on Friday, May 23, at The Carter Center. Seating begins at 1 p.m. President Carter as well as other friends and colleagues over the years, will offer remarks and reminiscences. The event will not be open to press coverage.

SOURCE: myMeso › Hamilton Jordan, Pres. Carter’s chief of staff, dies of mesothelioma

Nanotubes are tiny, cylindrical carbon molecules that, according to Wikipedia, exhibit extraordinary strength and unique electrical properties, and are efficient conductors of heat. They are already being used in sporting equipment like bicycle frames and tennis rackets due to their strength, and are thought to be the future of technology. They are used in some electronic components now, and are being researched to build tiny electronics and optics.

Researchers do not believe that materials containing carbon nanotubes are dangerous in and of themselves, in materials and products where they are safely encased, but are concerned about tiny nanotube fibers being released when those products are broken or incinerated. Also, they are concerned about workplace safety for nano factory workers.

The Washington Post reported that “preliminary evidence of cancer risk is strong enough to justify urgent follow-up tests and government guidance for nano factory workers.”

The National Institute for Occupational Safety and Health is conducting nanotoxicology research, and, according to a story in the San Francisco Chronicle, already recommends people working with carbon nanotubes follow NIOSH guidelines for working with engineered nanomaterials. This includes using respirators and special filters to clean the air.

It is estimated that nanotubes will be a $2 billion industry within the next few years, and nanoparticle technology and production even more than that.

The Washington Post points out that there is already significant federal spending in place to support this industry, with the National Nanotechnology Initiative providing about $1.5 billion a year for research. Only 5 percent of that fund is focused on health and safety.

While the carbon nanotube research is preliminary, its findings are significant enough to warrant real concern.

John M. Balbus, health program chief at the Environmental Defense Fund, made a prophetic statement to the Washington Post about the future of nanotechnology as it relates to public health. The paper quotes him as saying, “I think we are really coming to a critical juncture relating to transparency and stewardship. We will see whether various companies are going to be proactive and up front with people, and communicate openly in a way that inspires confidence and not repeat mistakes that other industries made in the past.”

SOURCE: myMeso › Nanotechnology linked to mesothelioma concern

In October 2007, the Senate companion bill, sponsored by Sen. Patty Murray (D-WA), passed. The House bill toughened the legislation, under the direction of the Environment and Hazardous Material Subcommittee of the House’s Energy and Commerce Committee, eliminating an exception for asbestos present at 1 percent or less by weight, making the ban a matter of federal statute rather than EPA regulation, and adding enforcement provisions.

The Meso Foundation reports the critically needed medical research funding provisions from Sen. Murray’s and Congresswoman McCollum’s legislation have not yet been added to the Committee Print.

In a statement released yesterday in support of including the research funding, the Meso Foundation said, “for the sake of all those already exposed, those now sick, and those who will be exposed in the future to asbestos already in place, we call on the Health Subcommittee to follow Sen. Murray and Congresswoman McCollum in recognizing the necessity of a robust asbestos disease research program, and to adopt the research funding provisions included in their legislation.”

Read the full story about this important legislation at Yahoo! News.

Supporters are urged to contact their Representative in Washington, DC, to urge inclusion of the research funding and swift passage of the complete bill once the funding is in place.

In Alabama, House Representatives are Robert Aderholt (4th Congressional District), Jo Bonner (1st), Mike Rogers (3rd), Spencer Bachus (6th), Robert E. “Bud” Cramer (5th) and Terry Everett (2nd). If you are not sure which is your congressional district, to locate contact information for your representative or to locate the representative for your state, visit the United States House of Representatives online, and click on your state for a list of your representatives.

Please contact your Representative NOW to let them know you support this legislation and to ask for their support. Please email me if you’d like any help!

SOURCE: myMeso › Action alert for Ban Asbestos and Prevent Mesothelioma Act

The results are based on a study of 409 patients, mostly from the United Kingdom, which set out to assess the potential benefits of combining active symptom control, which usually involves steroid drugs and radiotherapy, with chemotherapy. Results showed no real benefit from adding the chemotherapy drugs compared with just treating the symptoms of the disease.

The BBC quotes one of the authors of the study, Dr Richard Stephens from the Medical Research Council Clinical Trials Unit, as saying, “While thousands are and will be affected by this deadly disease, our trial, which is one of the few large trials ever conducted in this disease, emphasizes how difficult mesothelioma is to treat. This is mainly because mesothelioma forms in the lining of the lung. This makes it hard to target.”

One chemotherapy drug, vinorelbine, was shown by the study to have some promise, but researchers do not think blanket chemotherapy treatment is a promising direction for treatment of mesothelioma, according to the Lancet report.

Researchers do not necessarily consider these findings to be bad news, as a study that defines what does not help can be beneficial to patient health because it helps reduce the chance that patients will undergo stressful treatments that are ineffective.

Results of a completely different chemotherapy study conducted by researchers at Duke Comprehensive Cancer Center were released May 18, revealing that chemotherapy given in conjunction with cancer vaccines may actually boost the immune system’s response to the vaccines, according to a report by ScienceDaily.

The Duke study focused on a drug used to treat lymphoma, but could have implications for clinical trials with vaccines being used to treat many cancers including lung cancer, brain tumors and colorectal cancer.

According to the FDA, it is the goal of cancer vaccine clinical trials not to prevent cancer, but to treat existing tumors. The idea is to train the person’s immune system to recognize the living cancer cells and attack them.

In July 2007, the American Association for Cancer Research examined the issue of cancer vaccines and, according to a report by Medical News Today, they found that “ongoing therapeutic cancer vaccine trials have yet to show evidence of vaccines spurring a patient’s immune system to shrink tumors – yet patients who receive these vaccines in trials tend to live longer and respond better to subsequent treatment.”

The full study, titled Cancer Vaccines: Moving Beyond Current Paradigms is available to read online at Clinical Cancer Research.

Full results of the Duke study will be presented May 31 at the American Society of Clinical Oncology meeting in Chicago, Ill.

SOURCE: myMeso › Mesothelioma and chemotherapy research

Let me tell you a story about my loving Dad. He was my hero, he was my father. In December 2001 he came down with pneumonia and could never get rid of it. He didn’t really think that much about it at the time, and said the doctors were trying many different medicines to help him.

In February 2002 I got a call from my uncle that they figured my Dad had a stroke. My husband and I rushed from Memphis to Escanaba, Michigan. When we got there, what a shock! My dad had been a construction worker all his life, and was muscular and fit, especially in his upper body. He was a short man, about five-foot-five and 185 pounds. When we saw him in February, he weighed only 134 pounds. My husband and I were just shocked by his appearance, how sick he looked.

The doctor walked into the room and told my Dad, “Well, Warren, all the tests show that you did not have a stroke.” But they didn’t offer any answers about what was wrong with him. I thought, “Ok, what is going on?!” We took him home that day and I stayed with him for a week. He felt sure the doctors would help him, so I reluctantly went back home.

After I had been home in Memphis for about a week, a friend of the family called me and said, “Debi, you better get back here. Warren is not good.” I got on a plane immediately.

Dad lived in the upper part of Michigan where there are no major airports, so I flew into Green Bay, Wisconsin, and drove 2 hours to the house. As soon as I walked in, I saw that my Dad had gotten even smaller. He was down to about 110 pounds! His clothes would not fit him – they just fell off his body. I went to the store and ended up getting him a boys’ size 14, which he was able to wear. I couldn’t believe it. How could this happen? What was going on?

The next day I took Dad to the doctor’s office, and they told me he had pneumonia again. I just didn’t believe this, but I wasn’t sure what else to do. Shouldn’t I trust the doctors? But he just kept getting worse. He was wasting away in front of me.

From December 2001 to May 2002 my Dad had infection in his lungs 22 times. He continued to weaken, until we rushed him to the hospital on May 1. He was admitted, but it was a nightmare from that time on.

On May 10, the doctor came in Dad’s room and admitted he had no clue what was going on. I just lost it! I started yelling, “Look, this man is a veteran, and a retired Union man! He has three medical insurance policies. Get someone in here that can help him and can tell us what is wrong!”

They ended up flying in a doctor from the Mayo Clinic. As soon as he saw my dad and looked at his case history, he told me, “I have no doubt your father has mesothelioma.”

I had no clue what he was even talking about, let alone dealing with the fact that he had a cancer that kills in the end, and no one could tell me anything about this illness. You have to understand that back then, there in the upper peninsula of Michigan, there was very little internet access. I didn’t even know how to begin researching it.

Well, they took a piece of Daddy’s lung out for a biopsy, and on May 15 it came back as stage IV mesothelioma. I was just so mad that all this time had been wasted, while his health just deteriorated. It took me getting mad and fighting with them to even get a diagnosis!

I lost my hero on June 7 from mesothelioma. He died the same day my youngest son was to graduate from college. He missed out on that. We’ve missed out on so many things now. At the time of his death, my father’s weight was 76 pounds. I will never forget the way he looked.

Of course, now my family lives in fear that I will get this also from materials my Dad might have brought home from his work on Navy bases. My husband also is retired from the Navy with 23 years, and we worry about his exposure to asbestos. I already suffer from asthma and we worry what could happen if I contract mesothelioma.

Dad served in the Korean conflict at age 17, and no VA nursing home in the upper part of Michigan would take him because they didn’t know how to deal with his illness. I am on a mission every time this is something going on in D.C., from a trust fund to any bill, you bet this daughter of a Vet is on that hill fighting for the rights of meso victims! I will not stop!

Warren Faubert was 69 when he died of mesothelioma on June 7, 2002. He died less than one month after his official diagnosis.

SOURCE: myMeso › A dad’s tragic death from mesothelioma

According to a release on MARF’s web site, the Virtual Bank, which was four years in development, is the first mesothelioma research resource of its kind. The NMVB provides mesothelioma tissue samples from a variety of institutions, clinically annotated in a readily accessible database, to researchers in all mesothelioma investigations.

The Meso Foundation is the national organization dedicated to eradicating mesothelioma as a life-ending disease by funding the highest quality and most promising research projects from around the world through our rigorous peer-reviewed process; helping patients connect with national meso experts and obtain the most up-to-date information on treatment options; and advocating in Washington, D.C., for federal mesothelioma research funding to stop this national tragedy.

The Foundation has funded more than $5 million in mesothelioma research projects around the world, to date.

According to the MARF release, the NMVB is a collaborative effort of multiple organizations, including the Center for Disease Control and Prevention and the National Institute for Occupational Safety and Health, which together provided the initial $1 million grant for starting the tissue bank.

The release goes on to describe the NMVB as a bioinformatics system that combines assorted data from mesothelioma-related specimens into a single, annotated engine. The goal of the tissue bank is to expedite the discovery of preventive measures, novel therapeutic interventions and ultimately cures for mesothelioma.

For more information on the National Mesothelioma Virtual Bank, visit www.mesotissue.org.

The Meso Foundation will host its annual symposium to educate patients and families on the latest advances in meso research and treatment this year in Washington, D.C., June 26-28.

SOURCE: myMeso › National Mesothelioma Virtual Bank operational

According to the U.S. Department of Veterans Affairs, there are currently 25 million living individuals who have served in the United States’ armed forces. It is believed that a great number of them were exposed to toxic asbestos-containing materials during military service.

Every ship and shipyard built by the Navy before the mid-70s was fitted with numerous asbestos-containing materials. These materials were extensively used in engine and boiler rooms and other areas below deck for fire safety purposes, as well as in other areas of the ship. In fact, virtually no portion of a naval ship was asbestos-free between the 1930s and mid-1970s.

Unfortunately, veterans have little recourse when diagnosed with mesothelioma they believe to be the result of asbestos exposure during their time of service. Because asbestos use was so widespread before the first bans in the 1970s, it is very difficult for veterans to prove that asbestos exposure occurred only in military service.

Veterans are not legally allowed to seek compensation for mesothelioma and other asbestos-related diseases from the U.S. government through the court system. Ailing veterans must file a claim against the asbestos manufacturer, and they also have the legal option to seek assistance through The U.S. Department of Veterans Affairs (VA).

The VA is a government-run benefit system that is responsible for administering benefit programs to veterans, their families, and survivors. It is an incredibly complex system that comprises the second-largest federal department, after the Department of Defense. A search of the organization’s web site turns up no information about asbestos or mesothelioma. However, there are some organizations, such as Veterans Assistance Network (www.va-claim-help.com), that can help veterans wade through the VA benefits system.

Lung cancer is usually an indolent cancer that takes years to develop, thus the burden of treatment is falling most heavily on the VA. Late stage lung cancer is twice as costly to treat as early stage.

In February the Lung Cancer Alliance (LCA) announced that for the second year in row a coalition of top veteran organizations is calling for a screening program for veterans at high risk of lung cancer, to be included in the Independent Budget for Fiscal Year 2009 (FY09). This highly regarded comprehensive alternative budget addresses the most urgent needs of veterans, and urges Congress and the Department of Veterans Affairs to initiate a $3 million pilot screening program for veterans at high risk.

The AMVETS, Disabled American Veterans, Paralyzed Veterans of America and the Veterans of Foreign wars are the four co-authors of this document. More than 50 organizations support the Independent Budget.

A research program carried out by the International Early Lung Cancer Action Program at 40 centers in 26 states and 6 foreign countries during the past 13 years indicates that CT screening can detect lung cancer at Stage 1 in 85 percent of cases, and those treated immediately had a 10-year survival rate of 92 percent. By partnering with these types of programs, the Veterans Administration could quickly implement a pilot screening program for veterans at high risk, with a broad geographic reach and significant cost savings.

Rear Admiral Philip J. Coady, USN, (Ret.), chairman of LCA’s Board of Directors said, “Lung cancer continues to kill more men and women every year than all the other major cancers – breast, prostate, and colon – combined, and our veterans are at even higher risk, especially those whose active duty service exposed them to Agent Orange, asbestos, spent nuclear fuels, propellant gases and other carcinogens.”

Admiral Coady, a 34-year Navy veteran who never smoked, was diagnosed with lung cancer three years ago.

“Because there are usually no specific symptoms, most people are diagnosed so late they die within a year,” he pointed out. “Yet advanced CT technology that can diagnose lung cancer at its earliest, most curable stage is available right now, and high-risk veterans not benefiting from this is wrong,” he said.

Sources: asbestos.com, VAWatchdog.org

SOURCE: myMeso › Complicated path for veterans with mesothelioma

John was diagnosed with stage IV lung cancer a little more than a year ago at age 38. He was selected from among 56,000 people who entered a contest sponsored by Golf Digest, the United States Golf Association and NBC Sports to play the U.S. Open Course as part of the celebrity team. You can read more of his inspiring story at Golf Digest online.

In addition to raising awareness, John and the Lung Cancer Alliance would like to use this event as an opportunity to raise funds for lung cancer research. They are encouraging people to make a donation or pledge to LCA in John’s honor. There’s even a great idea for a “game day” event, where lung cancer awareness supporters can collect pledges and host a pledge party with family and friends. John is urging donors to consider doubling their pledge amount if he breaks 100!

Visit the Lung Cancer Alliance U.S. Open pledge page for donation information, pledge party forms, and links for help and more information.

What a GREAT opportunity to raise the profile of lung cancer awareness, and communicate to America – and beyond – what an important issue this is for national health! Watch for John in the coming weeks, as he is scheduled to appear on national news programs like NBC Nightly News, The Today Show and The Tonight Show. I’ll try to update when his appearances are scheduled.

SOURCE: myMeso › Lung cancer advocate Atkinson U.S. Open pledge

My Dad, Bill [Hackett], was a master mechanic and boilermaker from the time he was 25 until he retired on disability at age 61. During this time he dismantled and rebuilt or built boilers to run some of the company’s largest factories and businesses. He started out at Maryland Ship Building and Dry Dock and then went on to become an independent contractor.

Over the years he was exposed to asbestos hundreds of times, not knowing back then that it would be what eventually claimed his life.

From the time he was retired due to this disability until his death in 2004, he suffered tremendously with breathing disorders from mesothelioma. He faced several surgeries and had to have fluid removed from his body numerous times. There were days he could hardly breathe at all, but he kept going. How I will never know.

Because he had been self employed, there was no insurance because he could not afford it. And social security did not pay very much on a monthly basis. Being a decorated WW II veteran, he was entitled to some treatment through the Veterans Administration.

My father was a very independent man and refused to give up or give in to anything that stopped him from doing what he wanted and going where he wanted. And he refused to be a burden on any one, especially his daughters. Until the week he died he continued to serve as Chaplain of the American Legion Post and made arrangements for former veterans’ funerals and assisted their families.

But he never told us about the cancer. He went to all of his chemo appointments and never told us anything. It wasn’t until after his death and the Death Certificate was issued did we know this is what took him. He died alone, 2 weeks before Christmas, in the house where we grew up.

My dad was truly a great man. I believe the reason he never told any of us was because we lost our Mom to cancer when she was 34 and he was 36 and he didn’t want us to have to face losing him to cancer, even though it was a different kind.

Almost 2 years after his death, I found out that I have stage IV lung cancer.

Cancer in any form is life threatening. The more people are aware of the signs and symptoms of cancer, the better off they will be. Annual checkups are vital. Don’t wait until it’s too late. Cancer caught early can be cured. The later the stage, the more intense the treatments and the less chance for remission.

I’d just like to thank Nancy for sharing her Dad’s personal story with us, and for helping to raise awareness and urge for early detection and research. God bless you.

SOURCE: myMeso › A daughter remembers Dad

In the 2008 defense appropriations bill, Congress designated $50 million for the mesothelioma research as part of the Pentagon’s peer-reviewed program.

TheHill.com points out that supporters of the initiative for continued funding in the 2009 bill argue that “at least one third of the people suffering from mesothelioma … have either been in the Navy or worked in Navy shipyards across the country” where they were exposed to asbestos. Much of the exposure in the Navy cases, the report states, happened between World War II and the Vietnam War, when asbestos was used in shipyards and ships. For that reason, supporters push for federal funding for research.

TheHill.com writer Roxana Tiron reports that last month several senators sent a letter to the chairman and ranking member of the Senate Appropriations Defense panel in support of the continued funding. The letter stated, in part, “Funding through the Department of Defense appropriations bill is an important demonstration of our nation’s commitment to addressing the tragedy of mesothelioma and its disproportionate impact on those who serve our country.”

Among the bill’s supporters are Sens. Max Baucus (D-Mont.) and Patty Murray (D-Wash.), who have been leading the charge to ban asbestos and secure more funding for mesothelioma research. The Ban Asbestos bill, introduced by Murray and passed in the Senate last October, includes $10 million per year in funding for cancer research. The companion bill in the House has not yet been passed.

Also among the supporters for the 2009 appropriations funding for meso are Sens. Patrick Leahy (D-Vt.), Dick Durbin (D-Ill.), Barbara Boxer (D-Calif.) and John Ensign (R-Nev.).

The Meso Foundation funds approximately $1 million a year for research worldwide. The organization will hold its annual three-day symposium in Washington, D.C., starting on June 26, expecting more than 100 grassroots supporters to meet with their congressional representatives. For more information about this event, visit MARF online.

SOURCE: myMeso › DoD appropriations bill has meso funding request

Atkinson was selected from more than 56,000 entries, voted on by the magazine’s readers. Never a smoker, he was diagnosed with stage IV lung cancer a little more than a year ago at age 38. He hopes to use the golf event as an opportunity to raise awareness for lung cancer funding and research.

In a press release from the Lung Cancer Alliance, which urged its members and supporters to vote for Atkinson, he is quoted as saying, “The game of golf to me is living. I am going out there to enjoy the golf course, to play a great round and to give hope to those who are faced with life threatening illnesses. If I can beat America’s deadliest cancer, then I can definitely break 100 [at Torrey Pines]. It’s going to be a great day, an emotional day, and I can’t wait.”

Lung cancer is the nation’s leading cancer killer, taking more lives than breast, prostate and colon cancers combined.

To enter the contest, Atkinson submitted a 100-word essay describing why he could break 100 at Torrey Pines. Once being chosen as a finalist, he received more than 48,000 of the 117,000 votes cast in the first U.S. Open Contest, conducted by Golf Digest, the United States Golf Association, and NBC Sports. You can watch a video interview with Atkinson and read other features about the foursome at Golf Digest online.

SOURCE: myMeso › Lung cancer survivor to play on U.S. Open course

With a stage III diagnosis, she underwent chemotherapy treatments from October to December of that year, and then, faced with the prospect of a pleurectomy or pneumonectomy, which would remove part or all of the affected lung, decided to try alternative medicine.

Charlene went to the ITL Alternative Cancer Treatment Clinic in Freeport, Grand Bahamas, in January 2008, where she underwent an 8-week treatment called Immuno-Augmentation Therapy (IAT). Upon returning home, she administers her own vaccines several times a day, and has been continuing a twice-daily intravenous vitamin C program with the help of a nurse friend.

She celebrated her birthday Sunday, then on Monday went for her first CT scan since beginning her alternative treatment. Charlene reports, “There was overall improvement in my scan results!! The tumor was half of what it was previously, the pleural thickening was reduced, fluid is reduced and the pleural effusion is gone. I am thrilled, and stunned. Of course, I’m still guardedly optimistic, since I do still have cancer and the results could change at any time. But this, for now, this is the best birthday present I could have gotten!”

Alternative therapies like IAT are not authorized by the American Medical Association, and there is still a lot of skepticism and caution surrounding them. Generally, medical insurance does not cover alternative medical treatments like IAT.

Treatments that are not considered conventional medicine, but that are undertaken along with traditional medical therapies, like chemotherapy, radiation and surgery, are called complementary. Treatments used in place of conventional medicine, like the IAT Charlene is undergoing, are called alternative medicine.

IAT, along with other complementary and alternative medicine (CAM) programs, are being studied by the U.S. Department of Health and Human Services, the Food and Drug Administration (FDA) and the National Center for Complementary and Alternative Medicine (NCCAM), which operates under the Department of Health and Human Services.

Patients considering complementary or alternative treatments are encouraged to thoroughly research possible risks, benefits, and scientific evidence, and to discuss alternatives with their physician.

For more information, visit the NCCAM online, in the “health” section under “be an informed consumer.” They have information on topics including what to do when considering using CAM, how to select a CAM practitioner, and paying for CAM treatment.

I will be exploring CAMs in the coming weeks, and hope to talk to physicians and alternative and complementary treatment doctors and specialists about these programs, as well as patients like Charlene who are using them. If you’ve had an experience with a CAM, leave a comment or email me and share your experience.

I am thrilled for Charlene! Happy Birthday!!

SOURCE: myMeso › Living with Meso – Charlene’s story UPDATE

The study also will include environmental research.

Funding for the program will come from a special insurance fund overseen by the Department of Commerce.

SOURCE: myMeso › $4.9 million mesothelioma bill signed by Governor

To help you do this, and to help other visitors to myMeso.org find your story, we’ve added a new Meso Map feature. The Map is interactive, and will have markers showing where different people affected by mesothelioma, asbestos disease or lung cancer are located in the United States or around the world. Click on any marker on the map to read their personal story.

On the Map page, you can also access a form that makes it easy for you to submit your own story. You can share as little or as much personal information as is comfortable for you.

The Map can be easily found on the myMeso.org home page, at the top right – just look for the map with the words “Help Raise Awareness.” Or, visit this page directly by copying the link: http://www.mymeso.org/mesothelioma-stories-share-your-story and pasting it into your web browser.

Personal stories are SO important.

Telling your story may give you the outlet you need, to express the frustrations, joy, fear, successes, and anger – the whole range of emotions you experience.

Your story may provide guidance, comfort and a sense of community for people who are facing similar challenges. You may provide just the information about new clinical trials, about your experience with different treatment options, or an outstanding support group that is just what someone else is looking for.

Most of all, sharing your story will help us to put a human face on mesothelioma, which is critical to sparking action to fund research and find a cure.

Whatever you want to say, we’re ready to listen.

So please, visit our Meso Map page to read stories from mesothelioma and lung cancer survivors, and share your story!

SOURCE: myMeso › Meso Map puts a human face on mesothelioma

The study, which will be conducted under the direction of the University of Minnesota, will analyze death records and conduct screenings of current and former Iron Range mine workers and their families. To date, 58 Iron Range workers have died of mesothelioma. The study also will include environmental research, and is expected to last 5 years.

Funding for the program will come from a special insurance fund overseen by the Department of Commerce.

SOURCE: myMeso › $4.9M mesothelioma bill past House, to Governor

The Australian study, conducted by cancer research specialist Professor Julian Peto, was based on research into the lifetime occupations of 600 mesothelioma patients. Its findings were reported by the web site news.theage.com.au yesterday.

Peto predicts 30,000 Australians will die from mesothelioma between 2000 and 2050. He says the cause is exposure to both crocidolite asbestos (blue asbestos) and amosite (brown asbestos), which was used in building products in Australia and Britain until the 1980s.

According to the story on theage.com.au, Peto’s research reveals that Australia and the UK currently have the highest rates of mesothelioma in the world, with an estimated 600 cases per year in Australia and 2,000 in Britain, with numbers still rising.

Because I write this blog in the United States, I don’t talk as much about the looming global disaster asbestos poses. But it’s frightening, and it’s sickening, to see the effects of asbestos exposure just surfacing in communities around the world. I am afraid the coming suffering is unimaginable.

SOURCE: myMeso › Mesothelioma could kill 10% of Aussie carpenters

The bill now goes to the House, where a vote is expected Wednesday. If the bill passes the House, it will go to Gov. Tim Pawlenty, who is expected to approve it.

Originally, there was some dispute about the bill due to its funding source, but an amendment in the Senate resolved that issue. The money will come from a Department of Commerce fund that is reported to be operating with a surplus.

SOURCE: myMeso › $4.9M Mesothelioma research bill passes Senate

This week, I found a story that provides even more hope. It seems a Madison, Wisconsin-based biotech firm, Quintessence Bioscience, also has a promising mesothelioma drug in the works that operates along the same lines as ONCONASE, tagged QBI-139. The Quintessence drug is not yet in clinical trials.

Both drugs target RNA in cancer cells. They are therapeutic ribonucleases (RNases), which WTN News (Wisconsin Technology News) writer Steve Clark describes as “ubiquitous enzymes that destroy RNA.” He explains that researchers including the University of Wisconsin-Madison’s Ronald Raines, “discovered that RNases from non-human species sometimes are not regulated inside human cells and can cause cell death. Surprisingly, cancer cells are much more susceptible than normal cells to foreign RNases.”

The ONCONASE product is made from purified frog eggs. The Quintessence drug is 95 percent human, but still kills human cancer cells, Clark reports. Both drugs can kill a wide range of different human cancer types, he says, so its application has broad potential. The ONCONASE clinical trial data is from patients with malignant mesothelioma.

Clark reports that Quintessence is optimistic about its QBI-139 surpassing the positive results of ONCONASE. He says that frog-derived ONCONASE has been shown to cause allergic reactions in some patients, which would be mitigated in the 95 percent human-gene QBI-139. Additionally, he reports QBI-139 is less toxic than ONCONASE, which will allow it to be better tolerated by some patients in larger doses.

Currently, Clark reports, QBI-139 is being produced for use in a Phase I clinical trial, which is set to begin this summer and end sometime in 2009. It is anticipated that the trial will be held at the University of Wisconsin Carbone Cancer Center.

Read the full article at WTN News.

Steve Clark, Ph.D., is a former professor and medical researcher at the University of Wisconsin School of Medicine and Public Health, and is currently a freelance writer and consultant on biotechnology issues.

SOURCE: myMeso › New mesothelioma drug being developed

There was some controversy over the source of the funding when the bill was introduced in the House. Gov. Tim Pawlenty objected to the proposed funding source, a special state worker’s compensation fund, fearing it would raise premium costs for businesses that use the fund. The governor had threatened to veto the bill unless an alternate funding source was established.

An amendment proposed by the Minnesota Senate yesterday afternoon would fund the bill from a Department of Commerce fund, which is an “assigned risk” worker’s compensation fund.

The money will fund a five-year research project headed up by the University of Minnesota, which will review the health of miners and spouses, study the health records and occupations of miners who died and analyze the air quality in and around the mining communities.

The Senate has indicated support of the revised bill, with a final vote expected early next week. It will then move back to the House, where it also is expected to be met favorably.

According to TwinCities.com, a Pawlenty spokesman said the governor supports the amended bill and “believes it’s very important that this study moves forward.”

SOURCE: myMeso › $4.9 million mesothelioma research bill advances

During the program, which strives to answer the question “Why does anyone still die of cancer?”, Garmon visits the facilities where her husband was treated, and interviews people who are undergoing treatment for various types of cancer, and interviews doctors and researchers working for a cure.

PBS describes the film as, “Part science, part personal catharsis, part character-driven storytelling, this powerful documentary uncovers the truth about cancer and tell us where we stand in fighting the battle against the disease. ”

The program is slated to air in most markets at 9 p.m. ET. In Montgomery, Alabama, where I am based, the show is scheduled for 8 p.m. CT on WAIQ, Alabama Public Television (APT).

Following the film, journalist and breast cancer survivor Linda Ellerbee will host a 30-minute follow-up panel discussion covering topics including the importance of early screening, what to expect if a loved one is diagnosed, and how to live with cancer.

Please check your local listings for this very important program! It is critical to realize that cancer is an issue of national importance in public health, and that much more needs to be done to enhance funding and research for all types of cancer.

Find more information about this program at the official PBS site for the film.

SOURCE: myMeso › PBS film about meso, cancer airs

“A team of researchers led by Dr. Michele Carbone, director of the Cancer Research Center of Hawaii Thoracic Oncology Program and chair of pathology at the John A. Burns School of Medicine, has won the inaugural Landon Foundation-AACR Innovator Award for International Collaboration in Cancer Research.

The team discovered a unique mesothelioma epidemic in three Turkish villages was caused by a genetic predisposition to mineral fiber carcinogenesis. The researchers will apply the $100,000 grant to identifying the predisposing gene or genes for mesothelioma among this cultural group and map the genetic risk factors by genetic linkage studies.

Carbone’s researchers include those from the University of Hawaii, universities on the Mainland and the Hacettepe University School of Medicine in Ankara, Turkey.”

People that I’ve talked to who are affected by mesothelioma often wonder why they have this disease, oftentimes when many of their family members were exposed. They worry that their loved ones might contract this disease, but also puzzle about how it strikes one person out of many exposed similarly.

How exciting that new research may help point out genetic risk factors that could lead to better early screening and detection!

SOURCE: myMeso › UH mesothelioma research recognized

Following is the text of the open letter, along with information about how to contact Clinton’s office. The LCA is urging everyone affected by lung cancer, including mesothelioma, to join their voices in this effort to finally secure the funding that lung cancer has long deserved. It is time to make this a national priority!

An Open Letter to Presidential Candidate Hillary Clinton

April 9, 2008

Yesterday you announced what you would do for breast cancer should you be elected president. When will you announce what you would do for lung cancer?

The $300 million plan you unveiled yesterday to find a cure for breast cancer should be at least doubled for lung cancer since it is killing nearly twice as many women each year as breast cancer. Most women do not even know this.

You do, Senator Clinton, and you specifically cited that fact as part of the justification for Senate Resolution 87, which you co-sponsored and supported and which was passed August 2, 2007. The resolution was a strongly worded policy statement by the Senate calling on the President to declare lung cancer a public health priority and to implement a comprehensive interagency program to reduce lung cancer mortality by 50% by 2015.

The Resolution contains a page and a half of the grim statistics justifying the demand for priority action and specifically notes the enormous under funding of lung cancer research, which receives only seven cents for every federal dollar spent on breast cancer.

Of course we would like to see a cure for breast cancer as we would for all cancers. Thanks to the billions in federal dollars alone that have been invested in breast cancer research and early detection, the 5-year survival rate for breast cancer is now 88%.

Having been massively under-funded, as the resolution notes, lung cancer’s 5-year survival rate is still only 15%. That will no longer be tolerated.

We are not asking for a cure at this point. Just a 50% reduction in the mortality rate for lung cancer, the most lethal cancer, which is now killing more men and women each year than breast, prostate, colon, kidney, melanoma and liver cancers combined.

One in five women being diagnosed with lung cancer now have never smoked at all and they seem to be getting diagnosed younger. Why aren’t women demanding more research? Because they do not know the facts.

You spell out the facts so eloquently in S. Res. 87 and you lay out in the resolution a comprehensive program for lung cancer that is actually quite similar to the one you proposed yesterday for breast cancer.

When will you announce your comprehensive plan for lung cancer? We thank you and look forward to hearing from you on behalf of all those with and at risk for lung cancer, their families, caregivers and friends.

Lung Cancer Alliance

To contact Clinton’s office:

Hillary Clinton General Campaign Headquarters

4420 North Fairfax Drive

Arlington, VA 22203

Ph: 703.469.2008

Fax: 703.962.8600

comments@hillaryclinton.com

press@hillaryclinton.com

SOURCE: myMeso › Ask Clinton about funding lung cancer research

News24.com reported, in a story compiled by the South African Press Association, that trade union Solidarity expressed its support for the ban, and called on the government to also amend its asbestos dumping requirements or find alternative options.

The union also said that South Africa “could have followed the example of the rest of the western world and enforced this prohibition years ago,” according to the news story.

A related story published by TransWorldNews on Monday, April 7, stated that “in newly published documents by the Department of Environmental Affairs and Tourism [in South Africa], specific regulations have been introduced upon the use, manufacturing, import, and export of asbestos and asbestos containing materials.”

The report says that while some asbestos containing products, such as existing concrete shingles and ceilings, will not be immediately eradicated, the regulations call for the “phasing out” of such materials.

While the move toward this asbestos ban in South Africa is a positive step, it may be too little too late, according to Robert Jones, an environmental researcher with Rhodes University, who recently completed a study of several areas closest to now-closed asbestos mining sites in South Africa. Jones was a speaker at the recent Asbestos Awareness Day Conference in Detroit, Mich.

“South Africa is blessed with mineral resources – gold, diamonds, platinum,” he said. “And also cursed with mineral resources – asbestos.”

Between 1893-2001, South Africa mined all three types of commercial asbestos and was among the world’s leaders in asbestos mining and use.

Jones surveyed several communities within 2-5 km of the country’s largest asbestos mining sites, encompassing an area of approximately 7,000 square kilometers at each site. Assessment teams were made up of local people in the affected communities, and they targeted areas most suspect for contamination. Teams physically sampled soil and building materials from the locations.

While acknowledging that samples all came from high-risk areas where contamination was expected, the results were still staggering.

75-85% of homes surveyed are contaminated.

47-59% of schools are contaminated

53% of roads are contaminated

In many cases, the soil is blue with visible asbestos dust and clumps of asbestos fibers and minerals. Sports fields and schools are built on contaminated ground, and people build homes with mud bricks made from asbestos-contaminated soil. Some of the population has 24/7 exposure to contaminated soil. The ground is dry, and homeowners sweep bare ground into clouds of dust.

Jones likens the potential future of some of these areas of South Africa to “Libby (Montana) times forty.”

SOURCE: myMeso › South Africa is ‘Libby x 40′

After being diagnosed with mesothelioma at age 48, and exploring traditional options and undergoing four rounds of chemotherapy, Charlene Kaforey was looking for alternatives. Her physicians had earlier recommended a pleurectomy or pneumonectomy, which would remove part or all of the affected lung. That option was still on the table following chemo.

But after doing extensive research, Charlene was concerned about quality of life after such a procedure. Diagnosed as Stage III, she knew that only 25 percent of patients at her status survive 20 months, with less than 10 percent surviving 5 years. Both surgeries involve significant mortality rates and require 6-9 months recovery time.

“Currently, I don’t have a lot of symptoms,” she says. “I thought, why, if I feel good, do I want to end that by having the surgery and possibly never feeling good again?

“When I was at the hospital, I looked around the waiting room and saw everyone in wheelchairs, or hooked up to oxygen. I actually started crying. People don’t look good. They don’t look healthy, and they’re struggling. I thought, is this what’s going to happen to me? I didn’t feel a lot of hope.”

During her chemotherapy, from October-December 2007, Charlene researched mesothelioma and its treatments relentlessly. That was when she discovered the ITL Alternative Cancer Treatment Clinic, located in Freeport, Grand Bahama Island.

According to its web site, ITL Cancer Clinic was founded in 2003 and is directed by Dr. John Clement. ITL Cancer Clinic is the operating company for the Immunology Research Centre Ltd., a not-for-profit corporation of the Commonweal of the Bahamas, licensed to treat patients diagnosed with cancer. The Immunology Research Centre was founded in 1977 by Dr. Lawrence Burton, the developer of Immuno-Augmentive Therapy (IAT). The clinic treats all kinds of cancer, including mesothelioma.

Charlene’s daughter, working on a college project about promoting mesothelioma awareness inspired by her mother’s illness, discovered a web site with a link to the clinic. Charlene contacted the organization on whose site she found the link, to find out if they knew anyone who had been treated there. Initially, the answer was no. But two weeks later, they called her back and put her in touch with an ITL patient.

“I talked to her and she’s 6 years out,” Charlene said, which means the patient has survived six years after diagnosis. “She has it in both lungs and here she is, traveling and living life.”

Encourged, Charlene contacted the ITL Clinic directly for more information. Staff reviewed her medical history to see if she would be a candidate for treatment at ITL, and put her in touch with other mesothelioma patients being treated there.

“I’m skeptical by nature,” Charlene says. “It’s so out of the ordinary, but when I was talking to people out 6 years and feeling good compared to others who did more traditional treatments, some of whom didn’t make it very long, or life was hard, and it seemed like a good option for me.”

Friends and family initially resisted the idea, feeling that she should take the more traditional path, including surgery.

“People thought I was crazy at first. They had read all the literature [from traditional treatment facilities] and felt that I needed to do the surgery,” Charlene says. “Do I know for certain this will work? No. But I just don’t think the statistics support my having a good quality of life or a good chance of survival with surgery and traditional methods. So I’m going to do it.”

Next: The ITL Experience

SOURCE: myMeso › Living with Meso – Charlene’s story, Part 3

In the past two days, reports from local television stations in Minnesota representing the three main networks, CBS, NBC and ABC, say that Minnesota Governor Tim Pawlenty has spoken out against the bill currently before the state legislature, which would provide $4.9 million toward a study of mesothelioma and asbestos disease.

The news agencies report that Gov. Pawlenty objects to the fact that the proposed funding would come from the state’s Worker’s Compensation Fund. The Northland Newscenter, which operates channel NBC 6 and CBS 3 serving the Duluth area, said the agency in charge of that fund also opposes using money from the fund for the study.

The bill is currently moving through the Senate, and will be up for a vote on the House floor shortly.

SOURCE: myMeso › Minnesota governor questions meso funding

The conference was held at the Barbara Ann Karmanos Cancer Institute, which is the location of the National Center for Vermiculite and Asbestos-Related Cancers, co-directed by Dr. Michael Harbut and Dr. John Ruckdeschel, both of whom spoke at the ADAO conference.

While it might seem obvious, Dr. Harbut said, a key to diagnosing and treating asbestos disease is an emphasis on a medical approach.

Dr. Harbut explained that the Karmanos program “approaches asbestos disease from a purely medical standpoint, which includes taking into account any risk factors, employing state-of-the-art scanning equipment and a multidisciplinary, research-driven approach to early detection and treatment. This includes consideration of non-mailgnant or sub-clinical asbestos disease.

“Diseases that are ‘not hurting you yet,’” he said.

Focus areas at the National Center for Vermiculite and Asbestos-Related Cancers include the establishment of a schema for high resolution CT (HRCT) classification, measurement of pleural plaque volume, examination of psycho-social aspects of asbestos disease, testing new treatments including osteopontin and SMRP, and compiling a comprehensive database of disease, diagnosis and treatment.

The Center encourages anyone at risk from asbestos exposure to seek testing for early detection.

Dr. Ruckdeschel said barriers to successful asbestos disease treatment include a sense of nihilism in the medical community, the idea of giving up on the patient when mesothelioma is diagnosed due to its traditionally high mortality rate. There is a sense of providing only “quick fix” supportive care, he said.

Other challenges include a lack of treatment centers with a documented track record, lack of large standardized treatment trials, and a paucity of research investment, Dr. Ruckdeschel said.

The Center predicts an epidemic of vermiculite and asbestos-related cancers in the near future, as the latency period of asbestos disease exposure is reached, and as asbestos exposure spreads around the world, particularly in third-world countries.

“One life lost to asbestos disease is tragic. Hundreds of thousands of lives lost is unconscionable,” Dr. Ruckdeschel said.

For more information, visit the Karmanos Cancer Institute online or call 1-800-KARMANOS.

SOURCE: myMeso › Karmanos tackles looming asbestos epidemic

NEW YORK VOLUNTEER CHAPTER OF MESO FOUNDATION HOSTS THIRD ANNUAL5K WALK FOR HOPE

MERRICK, NY: The New York Volunteer Chapter of the Mesothelioma Applied Research Foundation (Meso Foundation) will hold the third annual “5K Walk for Hope” on April 13, 2008 at 10am in Eisenhower Park, located in East Meadow, NY. Over the past two years, the event has raised more than $30K and the volunteer team hopes to build on that success. All proceeds will go to the Meso Foundation, a 501 (c) (3) organization that has awarded more than $5 million in grants for mesothelioma research since 2000.

Mesothelioma is an extremely rare cancer caused by exposure to asbestos and most often affects the lungs, although it can also invade the stomach and groin areas. In the United States, 2,500 to 4,000 patients are diagnosed with mesothelioma annually, yet the disease has yet to find the national spotlight for research and funding.

The 9/11 tragedy in New York City demonstrates the continued, long-term threat of mesothelioma. Estimates of the amount of asbestos destroyed in the terrorist attack in Manhattan range as high as 1,000 tons. The impact pulverized this asbestos into tiny, microscopic fibers to which the firefighters, rescue workers, and other heroes of 9/11 were exposed, as well as workers, residents, and school children who returned to the area in the weeks and months following.

After mesothelioma’s long latency period, which is 15-50 years, the risk of cancer among those most heavily exposed could reach as high as one in ten. This year alone has seen the number of reported cases of illness and death of Ground Zero workers increase and unfortunately that number will only continue to rise, which is why more research is needed.

Registration for “5K Walk for Hope” is $15. Those who are interested in participating should contact Janice Malkotsis at (917) 751-2776. For more information about The Meso Foundation, please visit www.curemeso.org.

SOURCE: myMeso › Meso Foundation NY chapter Walk for Hope

The state Health Department in Minnesota has documented close to 60 deaths from mesothelioma in the Iron Range mining area.

According to the story published by The Globe, “The dean of the University of Minnesota’s School of Public Health [Professor John Finnegan, Jr.] is calling it ‘the best shot we’ve had in 25 years’ to find answers about a lung cancer that might be connected to mining taconite.”

If approved by the Minnesota legislature, the money would fund a combined study led by the University of Minnesota and including state health, natural resources and pollution control officials. The study would take about five years to conclude.

The Globe reports that the Senate bill has at least one more committee stop, and a House plan is also progressing. It says the plan faces some opposition from the business lobby, which is taking issue with the reliance on a workers compensation fund to pay for the research.

SOURCE: myMeso › Minnesota meso funding moving in Senate

When Charlene Kaforey, 48, was diagnosed with pleural mesothelioma in July 2007, she immediately began seeking out information and treatment options.

The prognosis for mesothelioma is still bleak. There is no cure, and most studies estimate survival time between 4-12 months, depending on the stage of presentation. Charlene’s mesothelioma was diagnosed relatively early, so she was hopeful.

She visited mesothelioma specialist Dr. David J. Sugarbaker at Brigham & Women’s Hospital in Boston, Mass., Dr. Valerie W. Rusch at Memorial Sloan Kettering Cancer Center in New York, and Dr. Harvey Pass at the NYU Cancer Institute.

Immediately, doctors talked about extrapleural pneumonectomy, a surgery to remove the entire lung, entire diaphragm, and the lining of the chest cavity and the heart. Surgery would be followed by 6 weeks of radiation, and possibly chemotherapy. One doctor even talked about performing a heated chemotherapy wash of the chest cavity while on the operating table. At that time, they believed Charlene was a stage I, and such surgeries could give her a 40 percent chance of a 5 year survival. One doctor mentioned getting her as much as 10 years.

One of the doctors talked about limiting the surgery to a pleurectomy/decortication, a technique to remove the parietal pleura from the lung. The median survival after pleurectomy for malignant mesothelioma ranges from 6-21 months, and 9-40 percent of patients survive up to 2 years. However in later stages, the survival rates are almost identical between the two surgeries.

Research is still unclear as to whether extra-pleural pneumonectomy provides significantly greater benefits than pleurectomy, and if either is significantly more effective than non-surgical options.

Charlene didn’t have a lot of tumor bulk, so she was sent for a mediastinoscopy, a biopsy surgery that allows doctors to view the middle of the chest cavity and to remove lymph nodes from between the lungs to test them for cancer or infection. They found that Charlene did have lymph node involvement.

“I went from a Stage I to Stage III overnight,” she says. “It was shocking.”

Because of the lymph node involvement, doctors recommended she postpone considering pleurectomy or pneumonectomy and undergo chemotherapy. Survival rates from either surgery for a Stage III patient is much less, and only 25 percent survive 20 months, with less than 10 percent surviving 5 years. Both surgeries involve significant mortality rates and require 6-9 months recovery time.

“Looking at it now, I feel in some ways that having the lymph node involvement was a godsend for me,” Charlene says. “I mean, my condition was more serious, but because I was doing the chemotherapy, it gave me time to look for more information and to really think more about my options. Otherwise, I would have rushed into a very serious surgery with a long, difficult recovery and I’d probably be without a lung and diaphragm right now.”

Charlene offers one word of caution to meso patients.

“While you may feel time is of the essence, don’t rush into a procedure until you really understand what is involved, and what benefits you can expect to receive, what the risks and complications are, how long and difficult the recovery will be,”she said.

She talked to other meso patients and read everything she could get her hands on. Quality of remaining life is a big issue to consider.

“I realized that I might have only 18 to 30 months maximum to live, and that I would spend at least 9 months in a brutal recovery. I was feeling good with little to no symptoms. I couldn’t justify giving up my good health to surgery, knowing I may never feel good again, and might have only another 9 months of poor quality life after recovering from the surgery,” Charlene says.

Next: Charlene explores alternative medicine

SOURCE: myMeso › Living with Meso – Charlene’s story, Part 2

Rear Admiral Phil Coady, U.S. Navy (Ret.), now serving as chairman of the board for the Lung Cancer Alliance, was never a smoker, and was surprised at the reactions of friends, family and co-workers when he told them he had lung cancer. They said he was brave for sharing the true nature of his illness.

“With lung cancer, there’s a real stigma attached to it. People don’t mention it in obituaries. There’s this perception that people with lung cancer brought it on themselves. I was never a smoker. Twenty percent of the women with lung cancer who are coming down with it every year have never been smokers.”

The stigma tends to inhibit discussion of lung cancer, Coady says, which impacts funding for research. If nobody is talking about it, the awareness just isn’t there, and it is treated as out of sight, out of mind. Meanwhile, lung cancer kills more people each year than breast, colon and prostate cancer combined. Ninety-two percent of people diagnosed with lung cancer die from the disease.

“I believe intently that the solution to lung cancer is making people aware that it is a public health problem and developing a public policy program. National priorities have not been adjusted to make this a national priority,” Coady says. “LCA’s first mission is to get before Congress to make this a national priority. Then, we go back to Congress and put some dollars behind it.

“The numbers we have all stated about the number of people who have died from lung cancer are compelling. It’s a half a million people every three years. There is no other cancer that comes close. But there’s almost no public funding.”

One current lobbying effort involves approaching state legislatures to gather support for an initiative that would donate 1 percent of tobacco tax revenue or tobacco liability settlements collected by state government for lung cancer research.

“Right now we’re using that money to build roads, schools, other infrastructure, but nothing to do with the cancer,” Coady said.

Next: Personal help for those with lung cancer

SOURCE: myMeso › LCA lobbies – Part 2 – the stigma of lung cancer

Frustrated, in the fall of 2006 she tried a new medication for a two-week protocol, plus a gluten-free diet for six months, and finally experienced some relief. But then, six months later, the pain and discomfort returned.

Since she had been off Crohn’s medications during the experiment with her diet, doctors decided it would be a good time to try some new tests, and included a CT scan. In March 2007, tests showed nothing wrong with Charlene’s stomach, but something odd at the base of her left lung. The doctor conducting the scan didn’t think it was anything serious, but recommended that she follow up with her primary care physician anyway.

In May 2007, Charlene received a chest CT scan, which revealed three spots on her left lung. Doctors suspected lymphoma. A cardio-thoracic specialist followed up with a PET scan, which showed the same three spots. He recommended a “wait and see” approach, suggesting they could check the area again in three to six months.

“I didn’t want to wait,” Charlene said.

At her request, doctors did a lung biopsy in July, and she was told she has mesothelioma.

The actual number of tiny tumors inside her chest were “too numerous to count,” and obviously most of those had not shown up on her scans.

“I’d never heard of it,” she says. “There are a few commercials on TV, but other than hearing the word, I was not familiar with it. Most people I tell just look at me, and they’ve never heard of it either.”

The diagnosis was particularly surprising, since the average median age of onset of symptoms is 70, according to most studies, and mesothelioma usually affects men more frequently than women. Charlene said she was exposed to asbestos when she was a child, but she cannot discuss the details because she is currently pursuing legal action.

“When you think of the numbers of people that have been exposed to asbestos in their lives, you wonder why there are few people that get [mesothelioma], as compared to other types of cancer. It’s still pretty rare,” Charlene said.

In the U.S. current statistics show between 2,000-3,000 people are diagnosed with malignant pleural mesothelioma each year. However, 10,000 Americans die each year from all asbestos-related diseases, according to statistics compiled by the Environmental Working Group. And, mesothelioma was not tracked as a specific cause of death by federal health officials until 1999, EWG points out, so actual totals for mesothelioma may be much higher.

“There is a possibility that my brother and my parents could be at risk of mesothelioma, because they would have been exposed at the same time as me,” Charlene worries. “You just don’t know what causes you to get it, and not someone else.”

As she continued to research her new diagnosis, Charlene was disheartened to find that the outlook for most mesothelioma patients is bleak. The Center for Mesothelioma and Asbestos-Related Diseases at the University of Maryland Medical Center estimates median survival time between 4-12 months after discovery.

Next: Charlene begins her fight.

SOURCE: myMeso › Living with Meso – Charlene’s story, Part 1

There seem to be conflicting opinions on this issue, with some experts saying that removal of vinyl flooring is relatively safe if proper precautions are followed, and others recommending that you call asbestos abatement professionals.

James Carey and Morris Carey, known as the Carey Bros., are nationally-recognized experts on home building and renovation. They share their 55+ years of experience as award-winning, licensed contractors with millions of people nationwide through a weekly radio program and syndicated newspaper column, both titled On The House. You can also find their information on their web site, at www.onthehouse.com.

The Carey Bros. recently addressed this issue. They point out that vinyl flooring usually comes in two forms – tiles and sheeting. They say the tiles are safer to remove because the asbestos is held together by the vinyl during removal.

The brothers report, “Folks licensed in asbestos abatement tell us that removing the floor in large chunks is reasonably safe. However, breaking it into little tiny pieces during the process could be dangerous.”

However, they also acknowledge that no amount of asbestos is considered safe. Research shows that ANY exposure to any amount of asbestos can be dangerous, because even one fiber can be inhaled and imbed itself in the lungs. Asbestos does not leave the body or dissipate over time. Once you are exposed, it is there. It may not necessarily cause asbestos disease, but you are at risk.

According to literature compiled by the Puget Sound Clean Air Agency and the Spokane County Air Pollution Control Authority, homeowners are warned that by removing materials potentially contaminated with asbestos themselves, they are accepting serious health risks.

Also, the Spokane publication points out that homeowners are liable when they choose to remove asbestos containing materials themselves. They note that “Your only legal options in having asbestos removed from your home are to hire a certified asbestos abatement contractor or do the work yourself. The law prohibits you from hiring anyone other than an asbestos abatement contractor to perform asbestos removal work. Family members and friends may participate legally, provided they do so as unpaid volunteers.”

The Puget Sound and Spokane guides are EXCELLENT resources for weighing the risks and options for this type of project. You can download a PDF version of the Vinyl Removal – How-to Manual or Asbestos-Vinyl removal warning documents. These are essential reading prior to starting a project like this.

Also, it is important to check to make sure that your state does not have any special legislation pertaining to asbestos-removal from a private residence. You may want to check with your local Homebuilders Association.

SOURCE: myMeso › Avoiding asbestos danger at home

Veglin is undergoing clinical trials at the University of Southern California’s Keck School of Medicine, and, in August 2007, MESORFA teamed up with doctors at the Yale Cancer Medical Center in an endeavor to meet the needs of the mesothelioma patients on the East Coast.

Veglin inhibits VEGF proteins, halting the formation of blood vessels and limiting the ability of tumors to grow and spread. Veglin is an antisense oligonucleotide, meaning that it can bond to messenger RNA (nucleic acid that directs protein production) and block the production of VEGF proteins.

Trials are targeting patients that have already undergone chemotherapy, and also newly diagnosed patients.

To determine if you qualify for Veglin, please contact Jennifer Paul, Executive Director, by calling 1-800-909-MESO (6376).

SOURCE: myMeso › MESORFA supports Veglin trials

SOURCE: myMeso › DoD funding for Meso research

This morning, WorkDay Minnesota published a series of stories about another quest for mesothelioma research in the state. Unrelated to the first grant, a Minnesota House of Representatives committee has approved legislation to allocate $4.9 million – to come from the state’s worker’s compensation special fund in fiscal year 2008 – for a special study of Iron Range mine workers’ deaths due to mesothelioma.

Inforum News writer Scott Wente reported today that the Minnesota Health Department in 2007 linked the deaths of 58 mining industry workers to mesothelioma. The University of Minnesota plans four studies related to the mesothelioma cases and other health issues for taconite industry employees and communities, according to the Inforum News story. Data points to an abnormally high rate of the cancer among the mine workers.

WorkDay Minnesota reports that in 2007, the state Department of Health announced that 35 miners, in addition to 17 previously identified, had died from mesothelioma. The number currently stands at 58 mesothelioma deaths.

The legislation for the funding must go through another House committee before getting to the floor, and the Senate has not yet held a hearing on the bill. If approved, the funding would direct the University of Minnesota to initiate a study this year and complete work by 2013.

The university’s School of Public Health will spearhead the project and already has set up a toll-free nurse helpline for questions on taconite worker lung health (1-888-840-7590) and launched a special website.

In the meantime, WorkDay Minnesota says that Friday the federal Mine Safety and Health Administration issued new rules that increase protections for miners who may be exposed to asbestos.

SOURCE: myMeso › Minnesota proposes $4.6 million Meso study

The group is a partnership between the University of Minnesota, Mayo Clinic and the State of Minnesota. Mark Paller is the partnership’s program director at the University of Minnesota. He said that projects were selected by a panel of national experts, who considered the potential for commercialization of the research.

Other topics for study covered by the grant are heart disease, infection prevention and epilepsy.

SOURCE: myMeso › Minnesota gets Meso research funding

• At least 741 people have been killed by asbestos since 1979 in Alabama.

• 10,881 people have sought justice in Alabama.

• At least 75 shipments (3,624 tons) of vermiculite went from Libby, MT to 4 locations in Alabama between 1948 and 1993.

About the Map

The dots on this map represent individuals who have died from two signature asbestos diseases, mesothelioma and asbestosis, as confirmed by death certificate records. To protect the identity of the victims, the dots on the map have been randomly placed within the county where the death was recorded.

The map includes just a small portion of all asbestos-related mortality that occurred during the time period analyzed. It does not include a single lung cancer death caused by asbestos, although national estimates of lung cancer mortality from asbestos range from 5,000 to 10,000 per year during that time.

The data also grossly underestimate mesothelioma mortality, the signature asbestos-caused cancer. This is in part due to under-diagnosis of the disease, but in greater measure because mesothelioma was not tracked by the federal government as a cause of death until 1999. Prior to that, scientists estimated mesothelioma mortality by assuming cancers of certain sites (for example, the pleura) were mesothelioma. This resulted in dramatic underestimates of the true mortality rates. When the government began tracking mesothelioma as a cause of death, mortality more than doubled, from 935 in 1998, to 2343 in 1999.

The map also does not include asbestos mortality from gastrointestinal (GI) cancer. The link between asbestos and GI cancer is contested by industry and its insurance companies, but OSHA and the World Health Organization International Agency for Research on Cancer all have concluded that asbestos does cause some types of GI cancer (OSHA 1994, WHO 1989). The best national estimates are about 1,200 asbestos-caused gastrointestinal cancers per year.

If the data presented above are corrected to include lung and gastrointestinal cancer and more accurate estimates of mesothelioma incidence, nationwide, the total mortality from asbestos from 1979 through 2001 would be about 230,000 people.

For more information about Asbestos in Alabama, visit the EWG report online.

SOURCE: myMeso › Asbestos Disease in Alabama

The study was based on the fact that because mesothelioma initially progresses on the surface of the pleura and peritoneum without forming masses, it has been difficult to diagnose at an early stage, so it would be useful to identify a tumor marker that would help in identifying it.

Researchers had previously identified N-ERC/mesothelin as a potential biomarker for mesothelioma. The recent study used a newly developed ELISA (enzyme-linked immunosorbent assay) system to gather data in clinical trials.

The report states that 102 healthy volunteers were recruited for the study, as well 39 patients diagnosed with mesothelioma, 53 patients diagnosed with diseases that should be distinguished from mesothelioma, and 201 subjects diagnosed with asbestos-related nonmalignant diseases.

The findings show that N-ERC/mesothelin is a “very promising tumor marker for mesothelioma, especially epithelioid mesothelioma.” Serum N-ERC/mesothelin levels showed that the median values from patients with mesothelioma were extremely high compared with levels from other patients.

Researchers participating in the study represented Juntendo University School of Medicine, National Organization Tokyo Hospital, Fukujuji Hospital, Hirano Kameido Himawari Clinic, Immuno-Biological Laboratories Co., Ltd., Hyogo Prefectural Tsukaguchi Hospital, Yokosuka Kyosai Hospital, St. Marianna University School of Medicine, and Tohoku University Hospital.

SOURCE: myMeso › Study may lead to early Meso diagnosis

Beginning in 2003, ACS started using the 2000 census for its age adjusted statistical analysis. Since that time, the incidence rate for lung cancer in men rose from 86 new cases per every 100,000 of population to 89, and incidence rates for women went from 51.4 to 55.2.

The LCA points out that in research dollars per death, lung cancer is receiving a fraction of the amounts given to breast, prostate and colon cancers.

The five-year survival rate for breast cancer now stands at 88 percent, prostate cancer 99 percent and colon cancer 65 percent, while lung cancer remains at 15 percent.

The ACS credits screening as a major component in achieving high survival rates. So, part of the problem, according to an article published in the Baltimore Sun Feb. 27, is that there is not yet any effective way to screen for lung cancer.

Reporter Stephanie Desmon found that neither physicians nor major medical societies advocate lung cancer screening at this time, because no one has proved that it saves lives.

Studies have shown that screenings find more cancer, but also more lesions and nodules that may or may not be cancer, Desmon’s report said. This leads to confusion about how to treat these spots, or whether to treat them at all. There also are concerns that lung screenings may lead to further tests, biopsies and surgeries, some of which may be unnecessary or harmful to a patient. Scans that produce “watch and see” results also lead to fear and anxiety, and emotional cost to the patient.

In 2002, the National Cancer Institute launched the National Lung Screening Trial (NLST), which will compare two ways of detecting lung cancer – spiral computed tomography (CT) and the standard chest X-ray. By Feb. 2004, nearly 50,000 people (smokers or former smokers) had joined NLST at more than 30 study sites across the country.

The trial (now closed to further enrollment) is slated to collect and analyze data for eight years to examine the risks and benefits of each type of screening. The NLST is a randomized, controlled study and is large enough to determine if there is a 20 percent or greater drop in lung cancer mortality from using spiral CT compared to chest X-ray. The trial is scheduled to last until 2009.

SOURCE: myMeso › Lung Cancer Leading Cancer Killer

Treating Mesothelioma

Because this is such a rare cancer, it has been hard for doctors to compare the value of different treatments. Since many doctors have little or no experience treating this disease, you may be referred to a specialist at a large medical center.Treatment options include surgery, chemotherapy and radiation therapy.One problem with treating mesothelioma is that it does not grow as a single mass. Instead it tends to spread along surfaces, nerves, and blood vessels. This makes it hard for one or more types of treatment to get rid of all of the disease.While surgery is not likely to cure the cancer, it might extend the patient’s life.Depending on the type and stage of the cancer, chemotherapy may be given as the main treatment or along with surgery. Chemotherapy for this disease is given to relieve symptoms, not to cure the cancer.As a rule, radiation treatment doesn’t help much for mesothelioma, and the need to treat a large part of the lung leads to problems with lung damage. But radiation can be used along with surgery to kill small areas of cancer that cannot be seen and removed during surgery. It can also be used as a way to ease symptoms such as shortness of breath, pain, bleeding, or trouble with swallowing. If fluid builds up in the chest, radioactive drugs can be put into the space after the fluid is drawn out. This might help keep the fluid from coming back.

New in Mesothelioma Research

There is always research going on in the area of mesothelioma. Much of this research has focused on learning exactly how asbestos changes normal cells and their DNA to cause cancer. Understanding how these fibers produce cancer might help us find ways to prevent those changes.Now that we know about the dangers of asbestos, we can limit or stop its use in homes, public buildings, and the workplace. But rules to protect people from asbestos are much less strict (or they do not exist at all) in some other countries.Research is also going on to learn about the role (if any) of a virus (SV40) that has been linked to mesothelioma in some studies.Because chemotherapy drugs have not worked very well against advanced mesothelioma, several new ideas are now being studied. These include drugs which kill cancers by stopping their blood supply and drugs which interfere with the ability of some cancer cells to grow quickly.Doctors are always learning more about the best way to treat people with mesothelioma. Treatments that combine surgery, radiation therapy, and chemotherapy are now being studied and may provide the most promising option for some patients.New drugs, along with other types of treatments, are now being tested in clinical trials.Another new approach is a type of gene therapy. This treatment uses special viruses that have been changed in the lab. The virus is injected into the space around the lungs where it infects the cancer cells. When this happens, the virus in turn injects a gene into the cancer that may help immune system cells to attack the cancer.

Research at UAB

The University of Alabama Birmingham (UAB) Comprehensive Cancer Center is a research and teaching hospital, and is currently conducting a number of studies on the treatment of mesothelioma.In 2005, UABs Spring/Summer magazine published information about ongoing studies being conducted by Katri Selander, M.D., Ph.D., a Cancer Center Associate Scientist, and Pierre Triozzi, M.D., about the effects of bisphosphonates on cancer cells.Bisphosphonates are drugs that are commonly used to treat and prevent osteoporosis. They also are used to treat metastatic breast and prostate cancers.The UAB article reported that Drs. Selander and Triozzi “have examined the effects of bisphosphonates on cancer cell cultures and in animal models, and have found that the drugs kill mesothelioma cells in both.” Further results of these studies were reported in the May 1, 2006 issue of Clinical Cancer Research, Vol. 12, 2862-2868; and in the European Journal of Pharmacology, Volume 559, Issue 1, dated March 15, 2007. Key points of the article in Clinical Cancer Research said that “the diagnositc use of radioactive bisphosphonates has revealed the accumlation of bisphosphonates in mesothelioma” and said that results of the studies “support further study of bisphosphonates in the management of mesothelioma.” The European Journal of Pharmacology report states that “Pre-clinical studies indicate that bisphosphonates also ihibit the growth of various cancer cells in vitro” and “in … mouse AB-12 mesothelioma cells.” For more information, visit UAB’s Comprehensive Cancer Center.

SOURCE: myMeso › Mesothelioma Treatment Options

What is Mesothelioma?

Mesothelioma cancer, or malignant mesothelioma, is an extremely rare disease generally affecting the lining of the lungs, and, more rarely, the abdominal cavity and/or the heart. Mesothelioma cancer is most strongly associated with exposure to asbestos, and can remain latent in those exposed for 30 to 40 years.

There are three types of mesothelioma cancer: pleural, in which the cancer affects the lining of the lungs/chest;  peritoneal, which affects the lining of the abdominal cavity; and pericardial, which affects the lining of the heart.

Pleural mesothelioma is the most common form of malignant mesothelioma, accounting for approximately three out of every four cases. The pleura is defined as the outer lining of the lungs and chest cavity. Pleural mesothelioma typcially has a latency period of 30-40 years or longer.

Peritoneal mesothelioma generally accounts for about 25 percent of maglignant mesothelioma cases diagnosed each year. It can have a shorter latency period than pleural mesothelioma, developing in 20-30 years or shorter. It affects the peritoneum, which is the lining of the abdominal cavity. Peritoneal mesothelioma generally occurs more often in males than females.

Pericardial mesothelioma, which affects the pericardium, the lining of the heart, is extremely rare. This form of malignant mesothelioma is usually fatal, due to its difficulty in diagnosis and treatment. It is generally diagnosed in a very late stage, and surgical or other treatment options are dangerous and difficult.

Mesothelioma in general is fairly rare in the United States. There are an estimated 2,000 to 3,000 new cases of mesothelioma each year in the United States. However, in European countries, especially the UK, as well as in Australia, the rate of mesothelioma is increasing.

For years, mesothelioma was thought to be  rare in people under age 55. Traditionally seen primarily in older men, usually with a background of working in a factory, shipyard, mine or other environment with heavy asbestos exposure, today more and more cases of secondary exposure are being diagnosed, and it is affecting greater number of women.

The average age for someone with mesothelioma used to be around 72, but each year it seems mesothelioma affects younger people, and a greater number of women. Last year, a 3-year-old girl was diagnosed with mesothelioma, stunning the physicians who were treating her.

Mesothelioma is a serious disease. By the time the symptoms appear and cancer is diagnosed, the disease is often advanced. The average survival time is about 1 year. The 5-year relative survival rate is around 10%, but this rate has been slowly improving.

The 5-year survival rate refers to the percentage of patients who live at least 5 years after their cancer is diagnosed. Many of these patients live much longer than 5 years after diagnosis, and 5-year rates are used to produce a standard way of discussing prognosis.

Five-year relative survival rates do not include patients dying of other diseases and are considered to be a more accurate way to describe the prognosis for patients with a particular type and stage of cancer. That means that relative survival only talks about deaths from mesothelioma. Of course, 5-year survival rates are based on patients diagnosed and initially treated more than 5 years ago. They may no longer be accurate. Improvements in treatment result in a more favorable outlook for recently diagnosed patients.

Symptoms of Mesothelioma

Early symptoms of mesothelioma can be very general. Thus, they are often ignored.

Symptoms of pleural mesothelioma (lining of the chest) can include:

* pain in the lower back or at the side of the chest

* shortness of breath

* trouble swallowing

* hoarseness

* cough

* fever

* sweating

* tiredness

* weight loss

* swelling of the face and arms

* muscle weakness

Symptoms of peritoneal mesothelioma (lining of the abdominal cavity) include:

* belly pain

* weight loss

* nausea

* vomiting

* fluid or a lump in the abdomen

Symptoms of pericardial mesothelioma (lining of the heart) include:

* constrictive pericarditis

* pericardial effusion

* cardiac tamponade

* heart failure caused by myocardial infarction

Of course, these same symptoms can also be caused by other minor ailments. But if you have worked with asbestos and you have any of these symptoms, you should see your doctor right away.

Diagnosing Mesothelioma

Diagnosing mesothelioma is often difficult, because the symptoms are similar to those of a number of other conditions.

Diagnosis begins with a review of the patient’s medical history, including any history of asbestos exposure. A complete physical examination may be performed, including x-rays of the chest or abdomen and lung function tests. As a rule, a chest x-ray is not useful in finding mesothelioma early.

One test being studied is a blood test. This test measures the levels in the blood of a certain protein that is higher in people who have lung damage due to asbestos. It is even higher if the person has mesothelioma.

A CT (or CAT) scan or an MRI may also be useful. A CT scan is a series of detailed pictures of areas inside the body created by a computer linked to an x-ray machine. In an MRI, a powerful magnet linked to a computer is used to make detailed pictures of areas inside the body. These pictures are viewed on a monitor and can also be printed.

A biopsy is needed to confirm a diagnosis of mesothelioma. In a biopsy, a surgeon or a medical oncologist (a doctor who specializes in diagnosing and treating cancer) removes a sample of tissue for examination under a microscope by a pathologist. A biopsy may be done in different ways, depending on where the abnormal area is located.

If the cancer is in the chest, the doctor may perform a thoracoscopy. In this procedure, the doctor makes a small cut through the chest wall and puts a thin, lighted tube called a thoracoscope into the chest between two ribs. Thoracoscopy allows the doctor to look inside the chest and obtain tissue samples.

If the cancer is in the abdomen, the doctor may perform a peritoneoscopy. To obtain tissue for examination, the doctor makes a small opening in the abdomen and inserts a special instrument called a peritoneoscope into the abdominal cavity.

If these procedures do not yield enough tissue, more extensive diagnostic surgery may be necessary.

If the diagnosis is mesothelioma, the doctor will want to learn the stage (or extent) of the disease. Staging involves more tests in a careful attempt to find out whether the cancer has spread and, if so, to which parts of the body. Knowing the stage of the disease helps the doctor plan treatment.

Mesothelioma is described as localized if the cancer is found only on the membrane surface where it originated. It is classified as advanced if it has spread beyond the original membrane surface to other parts of the body, such as the lymph nodes, lungs, chest wall, or abdominal organs.

New developments in Diagnosis of Mesothelioma

A recently published report in the Journal of the American Medical Association holds out hope for earlier detection of mesothelioma, a deadly cancer linked to asbestos exposure.

Researchers compared three types of endoscopic collection for accuracy in detecting cancerous cells in the lymph nodes to determine their accuracy.

Typically, doctors use several different techniques to diagnose lung cancers, including mesothelioma. Those techniques include physical exams, chest X-rays, CT scans and surgical biopsies to examine the cells in the lungs and the lymph nodes.

Lung cancer is one of the most common cancers worldwide, and the outcomes are typically unpromising. The low survival rates for lung cancer are often attributed to the difficulty of diagnosing the disease early enough for effective treatment.

This is especially true of mesothelioma, a disease that affects the tissues of the lining between the chest wall and the lungs. Often, by the time mesothelioma is detected, the cancer has reached untreatable stages.

Because of this, researchers are increasingly turning to new methods of detection that may identify deadly cancers at earlier stages when chemotherapy, surgery and other treatments may be effective.

The most accurate methods of diagnosis to date involve collecting cell samples from the lungs or lymph nodes for examination under a microscope. The most common method for collecting these cells is a mediastinoscopy, which is an invasive surgery that involves anesthesia and incision. The surgeon makes an incision at the top of the breast bone and inserts a thin, lighted tube into the chest cavity to withdraw cell and fluid samples.

Mediatinoscopy is typically used to determine whether fluids in the chest cavity contain cancerous cells or asbestos fibers.

In the past few years, doctors have developed less invasive procedures to collect tissue samples from the chest. These procedures use an endoscope, a small medical device that consists of a camera mounted on a flexible tube. Ultrasound probes, needles and other instruments can be inserted through the tube to remove samples for biopsy. These endoscopic procedures are far less invasive than more traditional methods, reducing the risks to patients who undergo them.

In the study reported in JAMA, researchers compared three different procedures using an endoscope, each of them considered minimally invasive:

• Transbronchial needle aspiration (TBNA)

• Endobronchial ultra-sound guided fine needle aspiration (EBUS-FNA)

• Transesophegeal endoscopic ultrasound-guided fine needle biopsy (EUS-FNA)

In each procedure, an endoscope was used to remove tissues or fluids with a fine needle. The researchers then compared the findings among the three methods to determine which was the most sensitive for detecting the presence of cancerous cells in the lymph nodes of the chest.

The study consisted of tests taken on 138 patients in the U.S. who were believed to have lung cancer. Each patient underwent all three procedures in sequence.

The results of the study showed:

- 30% (42) of the patients had malignant lymph nodes

- EBUS-FNA detected 29 of the cancers. TBNA only detected 15

- EUS-FNA and EBUS-FNA used in combination detected 93% of the cancers.

The combination was also able to detect malignancies in patients who would not have been identified by CT scans of the chest. The results of the study suggest that the minimally invasive procedures may be a viable alternative to more invasive standard procedures for evaluation patients believed to have lung cancer.

The lower risks associated with the procedure will make the diagnostic process more comfortable for patients and provide for a shorter recovery time.

Reference: Wallace, M, Pascual, J, Raimondo, M, et al. Minimally invasive endoscopic staging of suspected lung cancer. Journal of American Medical Association. 2008. 299(5) 540-546. Source: www.asbestos.com

New System May Give Lung Cancer Patients Hope

The Associated Press Aug. 31, 2007 http://www.msnbc.msn.com/id/20533486

Thousands more lung cancer patients each year could be offered surgery or other aggressive therapy under a new system that classifies many tumors as more treatable than in the past.

It is the first big overhaul of a decades-old method used to predict survival and help determine whether a lung cancer patient will have surgery, chemotherapy or be treated at all.

The new guidance is to be presented at a conference of lung cancer specialists in Seoul, South Korea, that starts Saturday. It is expected to be adopted by policy-making groups in the next year. Lung cancer is the world’s top cancer killer, claiming 1.3 million lives each year.

In the United States, 213,380 new cases and 160,390 deaths from the disease are expected this year. Nearly 60 percent of people die within one year of diagnosis, and nearly 75 percent die within two years, American Cancer Society statistics show.

In treating it, doctors use a formula called tumor staging. It is based on a tumor’s size, how far it has spread and other factors to predict a patient’s survival odds and to guide treatment.

More precise sorting

The current system was developed from about 5,000 tumor samples from University of Texas M.D. Anderson Cancer Center in Houston decades ago — before improved scanning technology was available to evaluate a cancer’s spread.

The new plan is based on 100,000 tumor samples from around the world including Asia, where lung cancer rates are projected to climb because of trends in smoking, unhealthy lifestyles and aging populations. It keeps four broad groupings but sorts people more precisely based on refined understanding of tumor characteristics.

The result: “There will clearly be shifting of patients from categories not operable to operable” — as many as 10,000 a year in the United States, said Dr. David Johnson, a lung cancer specialist at Vanderbilt University in Nashville, Tenn. He reviewed the plan, which was partly published in a medical journal recently.

The stage of the tumor at diagnosis is the best predictor of survival. Only 20 percent of cases are diagnosed in Stages 1 or 2, when tumors are small and confined to a lung, Johnson said. About 30 percent to 40 percent are found in Stage 4, after they have widely spread. The rest are in the middle.

Five-year survival rates are 47 percent for Stage 1 and 26 percent for Stage 2, but only 8 percent for Stage 3, and 2 percent for Stage 4, according to the American College of Surgeons.

Most lung cancers are the type called ”non-small cell,“ which is covered by the new staging system. The system was developed by the International Association for the Study of Lung Cancer, a group of lung cancer specialists from around the world.

Changing groupings

Dr. Peter Goldstraw, a surgeon at the Royal Brompton Hospital in London, led the project, and Canadian scientists independently validated the recommended changes by comparing survival across geographic regions.

Among the changes: creating more sub-stages for tumor size, reassigning some large tumors to a more advanced stage, reclassifying tumors that have spread into the fluid surrounding the lung, and recognizing that spread to certain lymph nodes is more dangerous than its spread to others.

“By changing some of these groupings, some patients will get moved to an earlier stage of disease for which we tend to be more aggressive” in treatment, said Dr. Joan Schiller, a lung cancer specialist at the University of Texas Southwestern Medical Center in Dallas .

“Before, a patient may have only been offered chemotherapy. They may now be offered chemotherapy and radiation,” or more intense radiation, she said. Conversely, some people thought to have earlier-stage tumors now will be grouped with those whose tumors have widely spread, and discouraged from undergoing therapies that have little chance of helping them.

“In some cases, patients were getting inappropriately aggressive treatment,” Schiller said.

Some people with very small tumors may get away with less therapy — taking out just a segment of lung instead of an entire lobe, said Dr. Stephen Swisher, a chest surgeon at M.D. Anderson.

The impact of the changes in Europe and Japan is unclear because doctors in those countries tend to remove whole lungs rather than lobes to treat lung cancer, Johnson noted. Doctors hope that ultimately survival will improve, but that won’t happen “unless we get patients into the right hands” and they get correct treatment, Johnson said.

Revising the staging system also will do little good if doctors don’t do the right tests to properly stage a tumor, said Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society. Staging for lung and other types of cancer should become even more precise in the near future as biomarkers and gene tests are developed to better sort patients, he added.

© 2007 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Risk Factors for Mesothelioma

The main risk factor for developing mesothelioma is exposure to asbestos.

Asbestos refers to a family of fibrous minerals made of silicate. Asbestos was once used in many products such as insulation, floor tiles, door gaskets, soundproofing, roofing, patching compounds, fireproof gloves and ironing board covers, and even brake pads.

As the link between asbestos and mesothelioma has become well known, the use of this material has almost stopped. Most use stopped after 1989, but it is still used in some products. Experts have linked this drop in asbestos use to the fact that the rate of development of mesothelioma is no longer increasing [in the U.S.].

Still, up to 8 million Americans may already have been exposed to asbestos. Exposure to asbestos particles suspended in air and building materials is much less hazardous except when they are being removed.

Since asbestos is a naturally occurring mineral, it can also be found in dust and rocks in certain parts of the United States as well as the world.

According to the U.S. Environmental Protection Agency, as many as 733,000 schools and public buildings in the country today contain asbestos insulation. As many as 10% to 15% of schools in the United States may contain asbestos insulation.

People who may be at risk for occupational asbestos exposure include some miners, factory workers, insulation manufacturers, railroad workers, ship builders, gas mask manufacturers, and construction workers, particularly those involved with installing insulation.

Several studies have shown that family members of people exposed to asbestos at work have an increased risk of developing mesothelioma, because asbestos fibers are carried home on the clothes of the workers.

The incidence rate for mesothelioma in men is dropping, probably because they are no longer being exposed directly to asbestos in their work. But the incidence rate for mesothelioma in women is steady, which suggests that they are being exposed in a way that is not directly tied to work, but more to their environment either at home or work. One example would be asbestos in buildings where they work or live.

A study from California also links mesothelioma to naturally occurring asbestos deposits in mountains.

Another important point about asbestos and mesothelioma is that the risk of mesothelioma does not drop with time after exposure to asbestos. The risk appears to be lifelong and undiminished.

There are 2 main forms of asbestos — serpentine and amphiboles. Serpentine fibers are curly and pliable. Chrysotile is the only type of serpentine fiber and it is the most widely used form of asbestos. Amphiboles are thin, rod-like fibers. There are 5 main types — crocidolite, amosite, anthrophylite, tremolite, and actinolyte. Amphiboles (particularly crocidolite) are considered to be the most carcinogenic (cancer-causing).

However, even the more commonly used chrysotile fibers are associated with malignant (cancerous) mesotheliomas and should be considered dangerous as well.

When asbestos fibers are inhaled, most are cleared in the nose, throat, trachea (windpipe), or bronchi (large breathing tubes of the lungs). Fibers are cleared by sticking to mucus inside the air passages and being coughed up or swallowed. The long, thin, fibers are less readily cleared, and they may reach the ends of the small airways and penetrate into the pleural lining of the lung and chest wall. These fibers may then directly injure mesothelial cells of the pleura, and eventually cause mesothelioma.

Asbestos fibers can also damage cells of the lung and result in asbestosis (formation of scar tissue in the lung), and/or lung cancer.

The risk of lung cancer among people exposed to asbestos is increased by 7 times, compared with the general population. Indeed, asbestosis, mesothelioma, and lung cancer are the 3 most frequent causes of death and disease among people with heavy asbestos exposure.

Peritoneal mesothelioma, which forms in the abdomen, may result from coughing up and swallowing inhaled asbestos fibers. Cancers of the larynx, pancreas, esophagus, colon, and kidney may also come from asbestos exposure, but the increased risk is small.

The risk of developing a mesothelioma is related to how much asbestos a person was exposed to and how long this exposure lasted. People exposed at an early age, for a long period of time, and at higher levels are most likely to develop this cancer.

Mesotheliomas take a long time to develop. The time between first exposure to asbestos and diagnosis of mesothelioma is usually between 20 and 50 years.

Other Asbestos-Related Cancer

Asbestos Related Lung CancerLung cancer, or bronchial carcinoma, occurs in several forms. The most common causes of lung cancer are smoking and asbestos.

This web site has focused on the most lethal of the lung cancers – mesothelioma. Not every asbestos-related lung cancer, however, is a mesothelioma. Other thoracic carcinomas, such as adenocarcinoma, are also caused by exposure to asbestos.

The connection between asbestos exposure and lung cancer was noted as early as 1925, and confirmed over the next 70 years by many epidemiologic studies of asbestos-exposed workers.

The four main types of commercially used asbestos, chrysotile, amosite, anthophyllite, and mixtures containing crocidolite, have all been associated with an increased risk of lung cancer. About one in seven people who suffer from asbestosis, a lung disease resulting from high exposure to asbestos, eventually develop lung cancer.

Asbestos is estimated to account for 3,400 to 8,500 new lung cancer cases in the United States each year. Like mesothelioma, the latency period between asbestos exposure and the development of asbestos related lung cancer may be two, three, four, or even more decades.

Very often, asbestos-related cancer victims also suffer from asbestosis, a scarring of the lung tissue caused by asbestos exposure. About one in seven people with asbestosis will eventually develop lung cancer.

Although commonly associated with lung cancer, adenocarcinoma is a type of cancer that develops in cells lining glandular types of internal organs, such as the lungs, breasts, colon, prostate, stomach, pancreas, and cervix.

Another type of adenocarcinoma, mucinous adenocarcinoma, accounts for only 10-15% of all adenocarcinomas and is particular to aggressive carcinomas that are comprised of at least sixty percent mucus. Non-small cell lung cancers make up over three quarters of all new lung cancer cases in the United States.

While there is only one type of small cell lung cancer, there are three types of non-small cell lung cancer. The three types of non-small cell lung cancer are squamous carcinoma, large cell carcinoma, and adenocarcinoma. When adenocarcinoma develops in the lung’s air sacs, it is called bronchioalveolar adenocarcinoma. About forty percent of all lung cancer cases diagnosed today are adenocarcinoma.

The progression of adenocarcinoma is quite unpredictable. In most cases, adenocarcinoma spreads slowly and causes very few lung cancer symptoms. But it can also be extremely invasive, aggressively spreading through the body and causing death before it can be treated. Given the disease’s variability, the five-year prognosis for patients with adenocarcinoma is dim: most are given only a 10 percent chance of survival.

Sometimes, tumors spread to the liver, adrenal glands, and bones, making adenocarcinoma much more difficult to treat. Symptoms of adenocarcinoma lung cancer may include shortness of breath, the coughing up of blood, fatigue, chest pains, and unexplained weight loss. Adenocarcinoma is usually treated with surgery, radiation therapy, and chemotherapy.

SOURCE: myMeso › What is Mesothelioma?

SOURCE: myMeso › Today is Mesothelioma Day 2008 in the UK

1. Sign the petition. The ADAO (Asbestos Disease Awareness Organization) has created a petition asking Congress to totally ban asbestos in industrial materials, consumer products and toys. Visit this website to add your name to this petition: http://www.gopetition.com/petitions/totally-ban-asbestos.html
2. Contact your Representative. Visit http://www.house.gov/ to find your Representative and write him or her to ask for careful consideration of this issue in the hearing, and in support of the Ban Asbestos in America Act of 2007.

On March 1, 2007, Senator Patty Murray (D-WA) introduced S. 742: Ban Asbestos in America Act of 2007 to the 110^th Congress. This is an act to amend the Toxic Substances Control Act to reduce the health risks posed by asbestos-containing materials and products having asbestos-containing material, and for other purposes. The bill is an effort to ban all production and use of asbestos in America, launch public education campaigns to raise awareness about its dangers and expand research and treatment of diseases cause by asbestos.The bill passed in the Senate on Oct. 4, 2007 by Unanimous Consent. A record of each representative’s position was not kept.The bill now goes on to be voted on in the House.

SOURCE: myMeso › Asbestos Hearing set for Feb. 28

Searches, news alerts, links – they invariably take me to stories written by the British media and posted to UK web sites and publications. The Press Association, the BBC, WebWire – just TODAY they had three stories about asbestos-related disease.

Stories urged workers likely to come in contact with asbestos to use precautions, wear protective clothing including filtered breathing units. Britain is having Mesothelioma Awareness Day Feb. 27.

Where is our news? Where is our information? The only time anyone in America has ever heard of Mesothelioma is when a loved one is shocked by a diagnosis.

Oh, and there is another time people hear about it. On commercials for law firms, which can tend to generate skepticism, scoffing, a sense that someone is trying to gain from someone else’s misfortune. Is that the truth?

The web site Asbestos.com recently talked to a professor of ethics at Washington University School of Law, Peter Joy. He said that asbestos lawsuits have, in fact, sparked many criticisms of the legal profession, and questions about the ethics of soliciting for clients.

But, he said, those who have suffered because of asbestos exposure have a different view of the situation. For many, faced with mounting medical costs, the right to bring suit against the companies responsible for their illness is their only recourse.

But shouldn’t they have known the danger their job might be posing? some ask.

Joy says no. He points out that the asbestos industry and others who knew and understood the dangers of asbestos to their workers and to the public showed complete callous disregard for general safety.

The Mesothelioma Information and Resource Group estimates that the connection between asbestos exposure and lung cancer was noted as early as 1925, and confirmed over the next 70 years. But, Joy says, the industry buried information about the dangers and hazards in the interest of maintaining higher profits.

Remember that the incubation period of Mesothelioma and other asbestos-related cancers is a long one, remaining latent in those exposed for 30 to 40 years. By the time the dangers of asbestos were told to the public, it was too late for many people.

Even now, asbestos is still not even completely banned in the U.S.

Asbestos litigators, Joy points out, have actually been responsible for raising public awareness about asbestos and mesothelioma. The result is that people have more information, and they are alert to their risk level. They seek early screening, which may save their life.

We certainly don’t see these stories in our media. Maybe a blip here, or a brief story here, then it’s gone again. People in the U.S. assume asbestos is yesterday’s worry. Surely that was years ago, right? That was fixed, wasn’t it?

Who else is going to help asbestos disease sufferers beat this drum, when the still-real danger has been so effectively swept under the rug?

Joy summarizes that it’s hard to fault methods and measures that bring about awareness, and help people in desperate need find a little bit of justice, whatever cold comfort that might bring.

SOURCE: myMeso › Who Cares About Us?

Asbestos is Leading Risk Factor for Mesothelioma

The main risk factor for developing mesothelioma is exposure to asbestos. Asbestos refers to a family of fibrous minerals made of silicate. Asbestos was once used in many products such as insulation, floor tiles, door gaskets, soundproofing, roofing, patching compounds, fireproof gloves and ironing board covers, and even brake pads. As the link between asbestos and mesothelioma has become well known, the use of this material has almost stopped. Most use stopped after 1989, but it is still used in some products.

Experts have linked this drop in asbestos use to the fact that the rate of development of mesothelioma is no longer increasing [in the U.S.]. Still, up to 8 million Americans may already have been exposed to asbestos.

Exposure to asbestos particles suspended in air and building materials is much less hazardous except when they are being removed. Since asbestos is a naturally occurring mineral, it can also be found in dust and rocks in certain parts of the United States as well as the world. According to the U.S. Environmental Protection Agency, as many as 733,000 schools and public buildings in the country today contain asbestos insulation. As many as 10% to 15% of schools in the United States may contain asbestos insulation.

People who may be at risk for occupational asbestos exposure include some miners, factory workers, insulation manufacturers, railroad workers, ship builders, gas mask manufacturers, and construction workers, particularly those involved with installing insulation. Several studies have shown that family members of people exposed to asbestos at work have an increased risk of developing mesothelioma, because asbestos fibers are carried home on the clothes of the workers.

The incidence rate for mesothelioma in men is dropping, probably because they are no longer being exposed directly to asbestos in their work. But the incidence rate for mesothelioma in women is steady, which suggests that they are being exposed in a way that is not directly tied to work, but more to their environment either at home or work. One example would be asbestos in buildings where they work or live. A study from California also links mesothelioma to naturally occurring asbestos deposits in mountains.

Another important point about asbestos and mesothelioma is that the risk of mesothelioma does not drop with time after exposure to asbestos. The risk appears to be lifelong and undiminished. There are 2 main forms of asbestos — serpentine and amphiboles.

Serpentine fibers are curly and pliable. Chrysotile is the only type of serpentine fiber and it is the most widely used form of asbestos.

Amphiboles are thin, rod-like fibers. There are 5 main types — crocidolite, amosite, anthrophylite, tremolite, and actinolyte. Amphiboles (particularly crocidolite) are considered to be the most carcinogenic (cancer-causing). However, even the more commonly used chrysotile fibers are associated with malignant (cancerous) mesotheliomas and should be considered dangerous as well.

When asbestos fibers are inhaled, most are cleared in the nose, throat, trachea (windpipe), or bronchi (large breathing tubes of the lungs). Fibers are cleared by sticking to mucus inside the air passages and being coughed up or swallowed. The long, thin, fibers are less readily cleared, and they may reach the ends of the small airways and penetrate into the pleural lining of the lung and chest wall. These fibers may then directly injure mesothelial cells of the pleura, and eventually cause mesothelioma.

Asbestos fibers can also damage cells of the lung and result in asbestosis (formation of scar tissue in the lung), and/or lung cancer. The risk of lung cancer among people exposed to asbestos is increased by 7 times, compared with the general population. Indeed, asbestosis, mesothelioma, and lung cancer are the 3 most frequent causes of death and disease among people with heavy asbestos exposure.

Peritoneal mesothelioma, which forms in the abdomen, may result from coughing up and swallowing inhaled asbestos fibers. Cancers of the larynx, pancreas, esophagus, colon, and kidney may also come from asbestos exposure, but the increased risk is small. The risk of developing a mesothelioma is related to how much asbestos a person was exposed to and how long this exposure lasted. People exposed at an early age, for a long period of time, and at higher levels are most likely to develop this cancer.

Mesotheliomas take a long time to develop. The time between first exposure to asbestos and diagnosis of mesothelioma is usually between 20 and 50 years.

Asbestosis

asbestosis – Asbestosis is a breathing disorder caused by inhaling asbestos fibers. Prolonged accumulation of these fibers in your lungs can cause scarring of lung tissue and shortness of breath. Asbestosis symptoms can range from mild to severe, and usually don’t appear until years after exposure.

According to information provided by the Mayo Clinic, symptoms of asbestosis include shortness of breath, initially only with exertion but eventually even while resting; decreased tolerance for physical activity; coughing, chest pain, and even finger deformity (clubbing) in some cases.

Asbestosis may cause such a reduced flow of oxygen as to be disabling or even fatal. It can also lead to complications like high blood pressure in the lungs, heart problems, lung cancer, other lung damage including those affecting the lining of the lungs and chest cavity, the pleura. These include pleural thickening and hardening (pleural plaques), and abnormal accumulation of fluid between the layers (pleural effusion).

Asbestosis itself does not increase your risk of developing mesothelioma, but it indicates that you were exposed to asbestos and therefore are also at risk for developing malignant mesothelioma.

Adenocarcinoma

adenocarcinoma (A-den-oh-KAR-sih-NOH-muh) – Cancer that begins in cells that line certain internal organs and that have gland-like (secretory) properties.

Although commonly associated with lung cancer, adenocarcinoma is a type of cancer that develops in cells lining glandular types of internal organs, such as the lungs, breasts, colon, prostate, stomach, pancreas, and cervix. Another type of adenocarcinoma, mucinous adenocarcinoma, accounts for only 10-15% of all adenocarcinomas and is particular to aggressive carcinomas that are comprised of at least sixty percent mucus.

Non-small cell lung cancers make up over three quarters of all new lung cancer cases in the United States. While there is only one type of small cell lung cancer, there are three types of non-small cell lung cancer. The three types of non-small cell lung cancer are squamous carcinoma, large cell carcinoma, and adenocarcinoma. When adenocarcinoma develops in the lung’s air sacs, it is called bronchioalveolar adenocarcinoma. About forty percent of all lung cancer cases diagnosed today is adenocarcinoma.

Like other cancers, adenocarcinoma is the growth of abnormal cells. These cancerous cells multiply out of control and form a tumor. In the lung, as the tumor grows, it destroys parts of the lung. Eventually, the tumor’s abnormal cells can spread (metastasize) to other parts of the body, including the local lymph nodes in the chest and the central portion of the chest, called the mediastinum; the liver; the bones; the adrenal glands; and other organs, including the brain.

Adenocarcinoma is more likely than other types of lung cancer to be contained in one area of the body. If it is truly localized, it may also respond better than other lung cancers to treatment, especially surgical removal of the tumor and draining lymph nodes.

Adenocarcinoma is the most common form of lung cancer. Most of this type of cancer is found in smokers. However, it also is the most frequent type of lung cancer seen in nonsmokers. It is the most common form of lung cancer seen in women and people younger than 45.

As with other forms of lung cancer, you are more likely to get adenocarcinoma if you:

• Are exposed to asbestos. Asbestos is a fibrous mineral that is used in home insulation, fireproofing, tiles for floors and ceilings, automobile brake linings, and other products. It is believed that asbestos fibers can cause lung cancer. People at risk of lung cancer include workers who are exposed to asbestos on the job (miners, construction workers, shipyard workers and auto mechanics who work with brakes), and people who live or work in buildings in which building products that contain asbestos are deteriorating. In addition to the adenocarcinoma type of lung cancer, individuals who have been exposed to asbestos, and particular types of asbestos, are also at a significant greater risk of developing a specialized type of lung cancer called mesothelioma.

• Are exposed to other carcinogens in the workplace. These include uranium, arsenic, vinyl chloride, nickel chromates, coal products, mustard gas, chloromethyl ethers, gasoline, diesel exhaust and high levels of talc dust.

• Smoke cigarettes. Smokers have 13 times more risk of developing lung cancer than nonsmokers. Cigarette smoke is associated with most cases of adenocarcinoma. Smoking is by far the leading risk factor for lung cancer, substantially more significant than all the other risk factors combined.

• Breathe cigarette smoke. Nonsmokers who inhale the cigarette fumes of smokers have an increased risk of lung cancer.

• Are exposed to radon gas. Radon is a colorless, odorless radioactive gas that is formed in the ground. It seeps into the lower floors of homes and public buildings and can contaminate drinking water. Radon exposure is the second leading cause of lung cancer. It’s not clear whether elevated radon levels contribute to lung cancer in nonsmokers. However, research has shown that radon exposure contributes to increased rates of lung cancer in smokers and in people exposed to higher levels of radon, such as miners. You can test the levels of radon in your home and surrounding area by using commercially available radon testing kits.

Your doctor will ask you whether you smoke or whether you live with a smoker. If you smoke, your doctor will ask you how much you smoke and how long you have smoked. Your doctor also will ask whether you have worked in an industry where you may have been exposed to asbestos or other carcinogens.

Call your doctor promptly if you have any of the symptoms of lung cancer, especially if you are a smoker or you have worked in an industry with high exposure to asbestos.

The outlook depends on the stage of the cancer and the overall health of the patient. In general, the prognosis is poor, especially if the lung cancer has spread to areas outside of the chest wall or has involved the lymph nodes of the mediastinum. This cancer can only be cured when surgery or radiation therapy can completely remove the tumor. However, many lung cancers are diagnosed at a stage when this is not possible. About 17 percent of people with adenocarcinoma survive more than 5 years after diagnosis.

Asbestos exposure increases the risk of lung cancer by nine times. A combination of asbestos exposure and cigarette smoking raises the risk to as much as 50 times.

A person who has had lung cancer is more likely to develop a second lung cancer than the average person is to develop a first lung cancer.

Repeated respiratory infections, such as bronchitis or pneumonia, can be a sign of lung cancer.

Asbestos Information

Asbestos and asbestos containing materials are responsible for causing asbestos cancer and asbestos disease cases around the world. Two of the most dangerous forms of asbestos disease are mesothelioma and asbestosis. Asbestos has been used in thousands of products for more than a century because it is highly versatile, abundant, and relatively cheap. Since asbestos is a naturally occurring mineral, it requires no manufacturing. Instead, asbestos only has to be mined, crushed, and added into products during the manufacturing process. Since asbestos is basically a rock, it is highly impervious to heat. It also happens to be chemically inert. Since its basic mineral structure is shaped in long, thin fibers, it can be broken down into these fibers to add strength and flexibility to nearly any product. A characteristic of asbestos is what is known as tensile strength. It allows products to be flexible yet strong while not adding excessive weight. Asbestos is one of few minerals that can actually be woven. Asbestos was commonly woven into materials that made excellent insulators, but were too brittle to be used by alone because they would crumble. Asbestos made insulation products flexible and durable since it was not affected by heat. Asbestos is not a very effective insulator by itself. All these qualities add up to a very useful and inexpensive product but some of them also make asbestos toxic to those that inhale asbestos fibers. There are six forms of asbestos characterized by differences in structure and color. Asbestos is also divided into two categories: serpentine and amphibole asbestos. Serpentine asbestos is made of curly fibers and amphibole asbestos is made of long, straight fibers. Both types of asbestos are considered dangerous, though it is thought amphibole asbestos forms, including crocidolite and amosite, may be more dangerous to humans.

Asbestos Exposure

Unfortunately, there are many opportunities for asbestos exposure since asbestos was used so abundantly in both industrial and consumer products. Most people that develop asbestos cancer and other asbestos diseases, including mesothelioma and asbestosis, usually have a history of chronic exposure to asbestos. Mesothelioma is somewhat unique in this respect, as mesothelioma cases have developed in people with limited asbestos exposure. As a result, there is no established “safe” level of asbestos exposure. Workers are exposed to asbestos when the substance or products containing asbestos are cut, crushed, sanded, drilled or otherwise disturbed. When left undisturbed, asbestos-containing materials can be relatively safe. In cases where asbestos materials are mined, installed, removed, demolished, or serviced, exposure can be a risk unless strict asbestos abatement techniques are employed. When inhaled, microscopic asbestos fibers can make it past the body’s natural defenses and deep into the lungs causing asbestos disease. Once within the lungs, the fibers can irritate lung tissue leading to asbestos cancer. If asbestos fibers make their way to the alveoli or air sacs in the lungs where oxygen and carbon dioxide exchange takes place, they can cause irritation and scarring called asbestosis. Asbestos fibers that pass through the alveoli and into the pleural mesothelium, can eventually lead to asbestos cancer in the form of tumors and malignant mesothelioma.

Asbestos Products

The following is a list of products that commonly contain asbestos:Roofing shinglesFelt and tar joint compoundCement pipesWall boardCeiling tilesSiding gasketsLaboratory hoodsMastics and sealantsBrake liningsFire doorsInsulation on some wiringCooling towersPaintTaping compound (thermal)Flexible duct connectorsGreenhouse materialsAppliance insulationSheet vinyl floor coveringPlaster sprayed-on fireproofingRefractory cement chalk boardsInsulation on steam pipesHeat resistant gloves and suitsAsbestos blankets Cork Board

Asbestos History

Asbestos was first discovered to be dangerous at the beginning of last century. It has been known as a carcinogen since the 1960s and was subsequently banned in more than 30 countries under grounds that there is no safe level of asbestos exposure. Mining and manufacture of most asbestos products has been ceased in the U.S., yet we continue to import more than 30 million pounds of asbestos in foreign products each year. A new recommendation by an EPA-sponsored panel of asbestos industry members and other experts on the topic called for a ban of all importation, manufacture, and mining of asbestos and asbestos containing products in the U.S. Although this may be a good sign, it also means that new risks of asbestos exposure are still developing. Since asbestos cancer and asbestos diseases take years and even decades to develop, many more cases of asbestos disease will be diagnosed.

Asbestos Legislation

On March 1, 2007, Senator Patty Murray (D-WA) introduced S. 742: Ban Asbestos in America Act of 2007 to the 110th Congress. This is an act to amend the Toxic Substances Control Act to reduce the health risks posed by asbestos-containing materials and products having asbestos-containing material, and for other purposes. The bill is an effort to ban all production and use of asbestos in America , launch public education campaigns to raise awareness about its dangers and expand research and treatment of diseases cause by asbestos. Murray’s legislation, which was first introduced in the 107th Congress, will also authorize additional studies to determine which commercial products today still contain asbestos, increase funding for asbestos-related diseases, and call for a national mesothelioma registry to help public health professionals track this deadly asbestos-related disease. Studies estimate that during the next decade, 100,000 victims in the United States will die of an asbestos related disease – equaling 30 deaths per day. The bill passed in the Senate on Oct. 4, 2007 by Unanimous Consent.

Currently, the companion to this bill, H.R. 3339, the Bruce Vento Ban Asbestos and Prevent Mesothelioma Act of 2007, is in committee in the House of Representatives. The House bill toughened the legislation, under the direction of the Environment and Hazardous Material Subcommittee of the House’s Energy and Commerce Committee, eliminating an exception for asbestos present at 1 percent or less by weight, making the ban a matter of federal statute rather than EPA regulation, and adding enforcement provisions. The bill must pass committee to make it before the full House for a vote.

Critically needed medical research funding provisions from Sen. Murray’s and Congresswoman McCollum’s legislation have not yet been added to the Committee Print. Supporters are urged to contact their Representative in Washington, DC, to urge inclusion of the research funding and swift passage of the complete bill once the funding is in place.

SOURCE: myMeso › Mesothelioma and Asbestos

The new system was developed by the International Association for the Study of Lung Cancer. I’m putting a link to the group in my blogroll, but it’s mainly full of professional development opportunities for doctors. But if you’re interested, it’s there.

Basically, the old system of “staging” a tumor (based on tumor size, how much it has spread, etc.) was developed from examining about 5,000 tumor samples gathered from the University of Texas M.D. Anderson Cancer Center, in Houston, DECADES ago. The new plan is based on 100,000 tumor samples from around the world, including Asia (predicted by ResearchandMarkets.com, particularly Japan, to see increases in cases of Mesothelioma due to the heavy use of asbestos there in the 1970s).

Doctors predict that the expansion of tumors for study and comparison will greatly increase understanding of tumor characteristics and allow them to better identify specific stages of tumor development beyond the four basic groupings (which will remain in place). They estimate that as a result as many as 10,000 patients a year in the United States will be shifted from inoperable to operable classifcations!

Changing some groupings, like creating more sub-stages for tumor size, reclassifying tumors that have spread into the fluid surrounding the lung, recognizing that spread to certain lymph nodes is more dangerous than its spread to others, and additional factors will let patients be classified at an earlier stage, where they can be recommended for more aggressive treatments.

Right now, only about 20 percent of cases are diagnosed in stages 1 or 2.

The article quotes Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society, who says that staging for lung and other types of cancer should become even more precise in the near future, as biomarkers and gene tests are developed that will even better sort patients.

Expanding the base of study from 5,000 samples limited to the U.S. – and one cancer center in the U.S. – to a base of 100,000 samples that includes international elements has to be good for the future of treatment. Just think how much more doctors can learn, and how much more variety they will be able to access to help them make a more accurate diagnosis!

SOURCE: myMeso › New system for staging lung cancer

There are links on this page to a number of web sites that provide medical information and information about asbestos, exposure to which is the leading cause of Mesothelioma. Check back regularly, as I will be adding to that list of links in addition to posting new information here.

Here is a good general definition, from the University of Alabama Birmingham (UAB) Medical Center, which has a Mesothelioma Clinic at its Comprehensive Cancer Center :

Q: What is mesothelioma and who is at risk?

A: Mesothelioma is an aggressive form of cancer in which cells of the mesothelium (the membrane that covers and protects most of the internal organs) become abnormal, form tumors, and grow without control or order. The disease usually affects the surface of the lung or less commonly the lining of the abdomen. It is relatively uncommon, with 2,500-3,000 new cases diagnosed in the United States each year. The major risk factor is working with asbestos, but the disease has been reported in some individuals without any known exposure to it. An experimental drug, Pemetrexed®, has shown promise in treating advanced mesothelioma. The UAB Mesothelioma Clinic and Comprehensive Cancer Center offer clinical trials for treating the disease. Early referral for the best treatment is important after diagnosis.

UAB is a research and teaching hospital, and is currently conducting a number of studies on the treatment of mesothelioma.

In 2005, UAB’s Spring/Summer magazine published information about ongoing studies being conducted by Katri Selander, M.D., Ph.D., a Cancer Center Associate Scientist, and Pierre Triozzi, M.D., about the effects of bisphosphonates on cancer cells.

Bisphosphonates are drugs that are commonly used to treat and prevent osteoporosis. They also are used to treat metastatic breast and prostate cancers.

The UAB article reported that Drs. Selander and Triozzi “have examined the effects of bisphosphonates on cancer cell cultures and in animal models, and have found that the drugs kill mesothelioma cells in both.”

Further results of these studies were reported in the May 1, 2006 issue of Clinical Cancer Research, Vol. 12, 2862-2868; and in the European Journal of Pharmacology, Volume 559, Issue 1, dated March 15, 2007.

Key points of the article in Clinical Cancer Research said that “the diagnositc use of radioactive bisphosphonates has revealed the accumlation of bisphosphonates in mesothelioma” and said that results of the studies “support further study of bisphosphonates in the management of mesothelioma.”

The European Journal of Pharmacology report states that “Pre-clinical studies indicate that bisphosphonates also ihibit the growth of various cancer cells in vitro” and “in … mouse AB-12 mesothelioma cells.”

For more information, visit UAB’s Comprehensive Cancer Center online at www3.ccc.uab.edu or click on the link in my list.

SOURCE: myMeso › Mesothelioma Research